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Traumatic brain injury (TBI) is a leading cause of death and disability. Despite its over-
whelming burden on sufferers, their families, and the health-care system; there are
no pharmacologic treatments that improve long term clinical outcomes. Drug devel-
opment for TBI has focused on mitigation of factors that contribute to the persistent
secondary injury from TBI. These target reactive oxygen species generation, cere-
bral edema, excitotoxicity, among others. Genomics has been a productive area to
support TBI drug development, and pharmacogenomics (PGx) - based drug use and
development has gained utility in critical care and TBI. This helps to identify new tar-
gets for treatment and/or prognostication, and to provide targeted therapy based on
an individual’s genomics. Our objective was to evaluate the role of drug transporters,
particularly the ATP-Binding Cassette transporter, ABCG2, following severe TBI. We
measured expression of transporters in experimental TBI, evaluated the association
of a missense genetic variation in ABCG2 with clinical outcomes from TBI, and studied
the change in disposition of the ABCG2 substrate, uric acid (UA), in patients with TBI.
We found that overall transporter expression tended to decreased acutely following
TBI, exemplified by ABCG2 expression, which was significantly decreased early follow-
iv
ing injury with a rapid return to baseline. The missense variation in the ABCG2 gene,
c.421C>A, was found to be associated with improved outcomes following severe TBI in
younger patients, suggesting that ABCG2 dysfunction is neuro-protective. Finally, we
discovered that patients with severe TBI who carry a variant allele at ABCG2 c.421C>A
have measurable decrease in UA transport in the CNS. These findings suggest that UA
is protective following TBI, which may be related to its role as an antioxidant. Future
study in this area can include further development of animal models for TBI that can
mimic human levels of UA, which are about 10-fold higher in humans than in most
other mammals. They may also include prospective observational trials to validate
the findings of UA’s association with ABCG2 and outcomes. Clinical trials of therapeu-
tic UA or the UA precursor, inosine, may also be warranted in patients suffering from
severe TBI.
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1.1 TRAUMATIC BRAIN INJURY OVERVIEW
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality among chil-
dren and young adults, contributing to nearly a third of all injury-related deaths.[2]
Lending to the complexity of TBI is the dearth of treatments that improve clinical
outcomes.[3] This problem requires the study of topics ranging from trauma, resusci-
tation, neuroscience, and molecular biology to understand the disease processes that
drive the neurologic damage that often leads to death or long-term disability in those
who suffer from TBI.
Our focus is on the development of novel treatment and prognostication modali-
ties for TBI by studying how changes in genetics impact TBI pathophysiology and out-
comes. Drug development can involve drug re-purposing and new drug development,
often drawing on pharmacotherapy from other disease states and patient-specific fac-
tors. This use of precision medicine in critical care is likely to support enhanced drug
development efforts in TBI.[4] We provide a review of the field of TBI pharmacother-
apy and current status of precision medicine as it applies to pharmacotherapy of TBI.
We also discuss the pathophysiology of TBI in addition to the standard and innovative
approaches to pharmacotherapy.
1.1.1 Epidemiology
Traumatic brain injury contributes to nearly 30% of all injury-related deaths.[5] The
most common causes for non-fatal TBI are from falls, motor-vehicle accidents (MVA),
and blunt injuries or blows to the head, which account for nearly 70% of all TBIs.[2, 5,
6] Leading causes of fatal TBI vary with age group, with falls predominantly affecting
individuals 65 years and older, self harm for individuals 25-65, MVA for 5-24, and
2
assault for children up to 4 years old.[5] Non-fatal TBI follows similar patterns, with
falls driving ED vists for everyone except for those age 15-24, for whom being struck
with an object is the leading cause.[5] TBI-related hospitalizations are driven by falls in
children up to 14 years old and in adults over 45, while other age groups are primarily
hospitalized for MVA.[5] Collectively, these injuries account for nearly three million
emergency department visits, hospitalizations, and deaths every year in the United
States.[5, 6] It is critical that drug development for TBI account for different ages as
the causes of injury and expected outcomes vary with age.[7]
1.1.2 Measurements of Injury Severity
Traumatic brain injury describes a diverse group of injuries ranging from concussions
(mild TBI) to moderate and severe injuries (e.g. MVA, combat-related injuries, se-
vere sports injuries, etc.). There are multiple competing clinical definitions of how the
breakpoints of TBI severity should be defined.[8] Commonly used TBI severity mea-
surements include the Glasgow Coma Scale (GCS) score, the Barell Type, the Injury
Severity Scale score, and the Abbreviated Injury Scale score, among others.[8, 9] The
GCS is commonly employed due to its simplicity, ability to be measured very early
following injury, and widespread familiarity. The GCS score is also validated for use in
clinical populations and is a strong predictor of mortality.[10] The complete GCS score
contains measures of motor response, eye opening, and the ability to communicate
verbally or make vocalizations (Table 1.1).[11]
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Table 1.1: The Glasgow Coma Scale[11] score is a composite measurement ranging
from 3-15. It comprises the sum of observed patient eye opening, response to verbal
commands, and motor response to stimuli.
Measurement Finding Score
Eye Opening Response Spontaneous opening with blinking at baseline 4
Opens to verbal command speech or shout 3
Opens to pain not applied to face 2
None 1
Verbal Response Oriented 5
Confused conversation but able to answer questions 4
Inappropriate responses; words discernible 3
Incomprehensible speech 2
None 1
Motor Response Obeys commands for movement 6
Purposeful movement to painful stimulus 5
Withdraws from pain 4
Abnormal (spastic); flexion decorticate posture 3
Extensor (rigid); response decerebrate posture 2
None 1
Ideally, GCS should be collected as soon as possible post injury by emergency
medical services or in the emergency department with follow up collections through-
out the patient’s hospitalization.[12] A limiting factor and disadvantage of the GCS is
that it should be collected in the absence of pharmacologic agents, especially sedat-
ing agents. Failure to obtain the uncontaminated GCS may lead to falsely low scores,
which may prevent accurate injury classification.[13] The Injury Severity Scale, Barell
Type, and Abbreviated Injury Scale may be collected later following injury, and may
incorporate the impact of trauma to other body systems.[8] These do not limit data
to brain injury, but can account for additional body regions, though severity infor-
mation for the brain injury can be abstracted from the total score. Another robust
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measurement for injury severity is derived from magnetic resonance imaging (MRI)
or computed tomography (CT) imaging data.[14] This can allow the clinician to bet-
ter understand the severity of the primary injury, the diffuse or local nature of the
parenchymal damage, and the location and extent of hemorrhage.[14]
Correlations with outcomes are commonly found among each scoring method,
though it is notable that GCS is most commonly used yet may not be the most corre-
lated with outcomes.[9] This may be because it is often collected very early following
injury at a time when the full breadth of the injury has not yet affected the patient,
or it is collected when the patient is sedated.[15] Despite its drawbacks, GCS is com-
monly used in addition to imaging data to prognosticate in the clinic and to control
for injury severity in TBI research. The GCS also has well established break-points for
injury severity, where a score of 3-8 is classified as severe TBI, 9-12 as moderate TBI,
and 13-15 as mild TBI.[8]
1.1.3 Measurements of Patient Outcomes
Outcomes from TBI are reported with the Glasgow Outcomes Scale (GOS) score and
GOS-Extended (GOS-E), both developed between 1970 and 1980.[16, 17] These pro-
vide detail regarding patient status that can be assessed quickly and have historical
use as outcome measures in clinical trials. Additional measures include the Disability
Rating Scale score, Neuro-behavioral Rating Scale score, and numerous others.[18, 19,
20] These assess more granular measures of outcomes at the cost of more overhead
required for collection.[18, 19, 20]
The GOS score is an ordinal scale ranging from 1-5 where 1=death, 2=persistent
vegetative state, 3=severe disability, 4=minor disability, and 5=no disability.[16] In
many clinical trials, the GOS is dichotomized with a sliding scale, most often defin-
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ing a favorable outcome as GOS > 3, and an unfavorable outcome as GOS ≤ 3.[21]
The dichotomous measurement provides practical interpretation of findings with some
notable drawbacks, including loss of robustness and statistical power.[21] Lu and col-
leagues suggest that GOS evaluated as an ordinal variable without dichotomization
may be less sensitive to data errors as well (e.g. a patient given a 3 when 4 is
more appropriate).[21] This requires more robust statistical methods and adds chal-
lenge to result interpretation, but is a reasonable way to improve the analysis of TBI
outcomes.[21]
1.1.4 Traumatic Brain Injury Disease Processes
1.1.4.1 Pathophysiology and Secondary Injury
Traumatic brain injury consists of several disease processes with temporal relation-
ship to the primary insult. The primary TBI relates to the physical injury, which can
be blunt or penetrating. This leads directly to damage from compressing, tearing,
and/or shearing of the parenchyma.[22] Furthermore, these injuries can lead to focal
damage within the brain, or they can cause varying degrees of diffuse injury. Dif-
fuse axonal injury (DAI) is associated with widespread axonal injury due to internal
stress from the primary injury, primarily resulting from shear stress from rotational
acceleration.[23, 24] These are assessed clinically with head CT and MRI scans, though
MRI is typically superior to CT scans in detecting DAI.[24] The primary injury requires
immediate medical therapy to resolve external damage, remove debris, and attain
hemodynamic stability. After resuscitation, attention must be diverted to preventing
progressive neurologic damage that can drive poor clinical outcomes. This progres-
sive response results from intrinsic factors related to injury repair, inflammation, and
physiologic changes and is referred to as secondary injury.[25]
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Hallmarks of secondary injury include changes in cerebral blood flow, loss of neu-
rovascular auto-regulation, hypoxia, and metabolic dysfunction. Punctuating these
pathways are progressive inflammation, damage from reactive oxygen species (ROS),
and glutamate driven excitotoxicity.[25, 26] Despite their value in growing under-
standing of TBI, in vivo and in vitro TBI models have shown limited success in trans-
lating pharmacologic therapies into clinical practice.[27] Innovative approaches are
critical to the successful discovery and development of TBI therapeutics. Methods that
combine individual patient characteristics with "big-data" (e.g. genomic, metabolomic,
transcriptomic) may provide the knowledge to eliminate the gap created by individual
and injury heterogeneity.[28, 29, 30]
1.1.5 Current State of Drug Development for Severe Traumatic Brain Injury
In contrast to other disease states with heavy burden on those suffering and on so-
ciety (e.g. cardiovascular disease), TBI does not have any available pharmacologic
treatments that are known to improve clinical outcomes.[31] This has sparked sub-
stantial drug development effort, with a growing list of drugs entering pre-clinical and
clinical trials. Efforts in TBI drug development have driven better understanding of the
disease processes around TBI, but gaps in our knowledge of basic disease processes
remain. This is driven by substantial injury heterogeneity and inter-individual variabil-
ity in disease course, which challenges our full understanding of TBI.[31] The search
for effective medications that improve severe TBI outcomes has included screening for
novel molecules, and work in re-purposing existing agents for TBI.[31] This effort has
involved translational research work involving pre-clinical in vitro and in vivo mod-
els, coupled with bio-banks and information repositories for patients suffering from
TBI. One such proponent of this strategy of drug development for TBI is Operation
7
Figure 1.1: Drug development for TBI is a translational process. As depicted, a
combination of translational studies that evaluate preclinical and clinical studies
ranging from large-scale human genomic association studies with other
clinical/preclinical techniques allows for rapid translation and validation of novel
findings. These inform the progress of TBI pre-clinical models to hasten translation to
human clinical trials.
Reprinted with permission from Pharmacogenomics[1] - See Appendix 3 Figure C1
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Brain Trauma Therapy (OBTT), which incoroporates multiple animal TBI models spread
across multiple research centers to study candidate drugs for TBI.[32] These efforts
are summarized in Figure 1.1.
1.2 PRECISION PHARMACOTHERAPY FOR TRAUMATIC BRAIN INJURY
Traumatic brain injury pharmacotherapy focuses on 1) resuscitation, 2) management
of the patient in the immediate post-injury phase, and 3) maintenance of the long-
term complications from TBI.[12] Patients frequently require intubation and intensive
monitoring, including neurologic assessments and frequent evaluation of cardio- and
neuro-vascular parameters.[33] Medications used during patient hospitalization in-
clude sedatives, analgesics, and neuromuscular blocking agents.
1.2.1 Pharmacotherapeutics and Pharmacogenomics for TBI
As with any disease state for which pharmacotherapy is indicated, medications fre-
quently do not work as expected. Adverse drug reactions (ADRs), toxicity, and inad-
equate response are common among medications, regardless of disease state.[34]
Advances in genomics have opened the opportunity for the use of genomic data
to tailor pharmacotherapy based on genetic variations (pharmacogenomics, PGx) in
genes for drug metabolism, distribution, and drug action. PGx with regards to TBI
promises the ability to tailor medication to patient baseline characteristics in addition
to disease specific situations. The use of PGx in the ICU presents new challenges
driven by the added complexity and heterogeneity of patient presentation and clinical
course.[35, 36] Current PGx evidence supports its use to inform medication selection
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and/or dose for seizure prophylaxis, analgesia, and sedation.[36, 37, 38]
1.2.1.1 Seizure Treatment and Prophylaxis
Post-traumatic seizures (PTS) can be clinical or sub-clinical in nature, and both types
can contribute to secondary injury.[39] PTS occur within seven days in as many as
22% of patients with moderate and severe TBI.[12] Current treatment guidelines rec-
ommend the use of seizure prophylaxis in the first seven days post injury to prevent
PTS. Based on work by Temkin and colleagues in 1990, the drug of choice for PTS pro-
phylaxis has been phenytoin.[40] However, a growing body of literature supports leve-
tiracetam as potentially equivalent or superior to phenytoin, [41] and potentially with
neuro-protective benefits [42] - particularly when treatment is continued daily into
the post-acute period.[43] PGx considerations for agents regarding PTS prophylaxis
and treatment can be divided into genetic predictors of drug response (i.e. traditional
PGx), and in PTS risk assessment (i.e. guided prophylaxis).
Pharmacogenomic predictors for phenytoin pharmacokinetics and response include
the cytochrome P-450, family 2, sub-family C, member 9 (CYP2C9) and the major his-
tocompatibility complex, class I, B (HLA-B), respectively. The Clinical Pharmacoge-
nomics Implementation Consortium (CPIC) and Dutch Pharmacogenomics Working
Group (DPWG) guidelines for phenytoin suggest that 1) patients with decreased CYP2C9
activity (e.g. CYP2C9 intermediate/poor metabolizers) receive a 25% to 50% lower
maintenance dose, and 2) patients carrying the HLA-B*15:02 haplotype should avoid
phenytoin due to over four-fold increased risk for severe cutaneous adverse reactions.[37,
38] Siddiqui and colleagues also reported that ABCB1 rs1045642 (GG) was asso-
ciated with higher incidence of drug-resistance epilepsy (Odds Ratio: 2.66, 95%CI:
1.32, 5.38), which suggests that some anti-epileptic drugs’ ability to cross the blood-
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brain barrier (BBB) and/or the intestinal brush border may be impacted by ABCB1
function.[44] However, this finding has not been directly linked to phenytoin, and
additional studies have not supported a significant contribution of variations in the
ABCB1 gene to phenytoin pharmacokinetics and pharmacodynamics.[45, 46] These
PGx markers may be useful in TBI to identify patients who may require lower main-
tenance doses or an alternative agent, such as levetiracetam, during PTS prophylaxis
and treatment.
The use of genetic markers to predict risk for PTS may help guide therapeutic deci-
sion making for individual patients. The adenosine A1 receptor (ADORA1) rs3766553
(AA) was associated with over five-fold increased risk for PTS in a study with 206
subjects with severe TBI, although the mechanistic basis was not established by this
association.[47] Kochanek and colleagues evaluated the impact of Adora1 knock-out
(KO) in a murine model for experimental TBI and found that KO mice develop lethal
status epilepticus following TBI, suggesting a role for ADORA1 in preventing PTS.[48]
Activation of ADORA1 seems to inhibit the microglial response following TBI, which
may indicate that ADORA1 and its associated pathways represent a therapeutic op-
tion for TBI.[49] These findings not only suggest new treatment modalities for PTS,
but may help identify patients more likely to benefit from PTS prophylaxis. Darrah and
colleagues investigated the glutamic acid decarboxylase 1 and 2 (GAD1/GAD2), which
catalyze the conversion of glutamate to GABA. In a study of 257 adults with severe TBI,
they found that GAD1 rs3828275 (CT,TT) was associated with higher risk for PTS (Odds
Ratio: 5.6, 95%CI: 1.21, 25.90).[50] Apolipoprotein E (APOE) has been studied for its
role in PTS, and some investigations have suggested an association between APOE
ε4 homozygotes and PTS, but this finding has not been consistent.[51, 52] Variability
in outcome measures, statistical power, patient characteristics, and methodologies
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seems to be the driver of this variability; however, a systematic review by Lawrence
and colleagues found that over 63% of studies investigating APOE ε4 was detrimental
to outcomes post-TBI.[53]
1.2.1.2 Sedation and Analgesia
In the intensive care setting, sedation is used to minimize patient discomfort and con-
trol intracranial pressure (ICP) in patients with TBI.[12] Preferred agents for sedation in
adults with TBI include propofol and midazolam due to their favorable effects on cere-
bral metabolism, ICP, and cerebral perfusion pressure (CPP).[54, 33, 55] Midazolam is
metabolized by cytochrome P-450, family 3, sub-family A, member 4/5 (CYP3A4/5) en-
zymes. The CYP3A5*3 haplotype is associated with decreased midazolammetabolism,
but its effect may only be clinically relevant in the presence of concomitant moder-
ate/strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin).[56, 57, 58] Ketamine
and dexmedetomidine may be used in some patients with TBI as adjunctive or solo
agents due to decreased accumulation, lower risk for dependence, and/or ease with
which patients can be awakened for neurologic assessments. Nevertheless, their
use in routine clinical practice for TBI is less established, but their use has gained
popularity.[33] Some studies assessing ketamine in for ICP control among individu-
als with severe TBI have suggested that it provides sedation with minimal impact
on ICP, although this remains controversial.[59] Ketamine is primarily metabolized by
CYP3A4, but at higher concentrations the metabolic contribution of cytochrome P-450,
family 2, sub-family B, member 6 (CYP2B6) is more pronounced.[60] Li and colleagues
found that CYP2B6 (*6/*6) was associated with 59% and 40% decreased steady state
clearance of ketamine compared to CYP2B6 (*1/*1, *1/*6), respectively in a group
of 49 adult patients.[61] Decreased clearance of ketamine may increase risk for ad-
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verse events including adverse psychomimetic and cognitive reactions, and hepatic
and/or renal toxicity.[61, 62] Variability in dexmedetomidine pharmacokinetics/phar-
macodynamics may be explained by variations in its metabolic pathway through the
cytochrome P-450, family 2, sub-family A, member 6 (CYP2A6) and UDP glucuronosyl-
transferase family 1 member A4 (UGT1A4), though no link has been found at this point.
However, dexmedetomidine pharmacodynamics may be affected by variations in its
target, the adrenoreceptor alpha 2a (ADRA2A).[63, 64] Yagar and colleagues found
that ADRA2A rs1800544 (GG, GC) was associated with slightly decreased efficacy at
some time points as measured by sedation scores, though the clinical relevance of
this finding is not clear.[65] Barbiturates, particularly pentobarbital, are also used as
sedatives for TBI patients with refractory intracranial hypertension.[12]
TBI patients may also receive therapy with opioid analgesics/sedatives like fen-
tanyl, remifentanil, or morphine.[33] Variants in ABCB1, CYP3A5, and the μ opioid
receptor 1 (OPRM1) drive variable response to opioid medications commonly used for
TBI.[66, 67] ABCB1 rs1045642 (TT) is associated with decreased expression of ABCB1,
which may increase penetration of ABCB1 substrates across the intestinal epithelium
and the BBB. Fentanyl and morphine are substrates for ABCB1, and individuals car-
rying ABCB1 rs1045642 (TT) may require lower doses. Lotsch and colleagues mea-
sured oral morphine equivalent dosing in subjects treated with ABCB1 substrates (e.g.
morphine, fentanyl). They found that subjects with ABCB1 rs1045642 (TT) required
135.4mg vs (CT) 194.9mg vs (CC) 274.5mg (ANOVA p = 0.014).[66, 68] Similarly,
Horvat and colleagues found in a diverse pediatric population (N=61) that patients
with ABCB1 rs1045642 (TT) required 18.6mcg/kd/day less fentanyl than (CT,CC).[69]
Patients with CYP3A5*3 may also require a reduction in dose of fentanyl due to de-
creased hepatic clearance.[68] The OPRM1 variation rs1799971 (GG) is associated
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with decreased efficiency of endogenous opioid signaling.[70] OPRM1 rs1799971 (GG)
may predict increased dosing requirements for analgesics, and individuals with AG or
AA genotypes may experience higher rates of adverse reactions.[67, 36]
1.2.2 Long Term Rehabilitation
Chronic neurologic and psychiatric care is necessary for many individuals post-TBI and
pharmacotherapy may be guided by PGx. The use of PGx concepts to guide treat-
ments for TBI rehabilitation in light of genetic risk factors and expected response
to medications complements the rehabilomics framework introduced by Wagner in
2010.[71] Rehabilomics in the context of TBI refers to systematic use of biomarker,
genetic data, phenotype data, and other patient specific factors that impact rehabil-
itation and long-term recovery.[71, 72] It focuses on TBI as a chronic disease state
that requires long term care with patient-specific approaches to rehabilitation. An
example of this is found in the approach by Myrga and colleagues in evaluating the
sex-stratified risk for post-TBI cognitive decline in association with dopamine path-
ways. They found an important sex * gene interaction in patient outcomes, sug-
gesting sex associated stratification of genetic risk.[73] While rehabilomics is all-
encompassing, PGx is most applicable in the psychiatric and neurologic pathologies
requiring pharmacotherapy such as post-traumatic depression (PTD), cognitive de-
cline, and post-traumatic epilepsy (PTE).[74, 72] PTD and changes in cognitive ca-
pacity are multi-factorial, but incidence, nature and onset, as well as severity and
duration may be predictable through genetic risk factors associated with monoamine
pathways, specifically the dopamine (DA) pathways in the pre-frontal cortex and by
serotonin pathways.[73] PTE may share some risk factors with PTS, but is thought to
have unique pathophysiology.[75] Genetic influences on risk for these complications
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are summarized in Table 1.2.
1.2.2.1 Post-Traumatic Depression
Post-traumatic depression occurs in up to 50% of individuals in the first year after
TBI.[91] Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants
(TCAs) are frequently prescribed antidepressants, yet require up to six weeks to have
an effect and have a poor response rate (the first choice only works in about 50%
of individuals).[92] This necessitates a trial-and-error approach to antidepressant se-
lection, which can result in patients waiting several months before finding an optimal
therapy. Understanding if and how genetics moderates premorbid psychiatric disease
relationships to PTD risk is an important consideration. The 5-HTTLPR variation is a
tandem repeat in the promoter region for the serotonin transporter gene; SLC6A4,
which is defined as either long (L) or short (S). L-homozygotes for this variation were
found by Failla and colleagues to be at nearly three-fold higher risk for PTD, which may
help to select patients who should be treated with antidepressants (e.g. SSRIs).[89]
Genetic predictors of risk for depression may be augmented by published PGx
guidelines for selection and dosing of SSRIs when genetic data are available. De-
creased doses of citalopram, escitalopram, and sertraline are recommended in cy-
tochrome P-450, family 2, sub-family C, member 9 (CYP2C19) poor metabolizers.
Citalopram and escitalopram are not recommended in CYP2C19 ultra-rapid metab-
olizers. Paroxetine and fluvoxamine are metabolized by cytochrome P-450, family
2, sub-family D, member 6 (CYP2D6). Paroxetine is not recommended in ultra-rapid
metabolizers or poor metabolizers at CYP2D6, and a 25-50% dose reduction for flu-
voxamine is recommended in poor metabolizers at CYP2D6.[93] Information about
depression risk and drug metabolism may help clinicians appropriately monitor pa-
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Table 1.2: Drug-Gene Pairs for Traumatic Brain Injury
Gene HG38*/Common Name rsID Genotype(s) Complication References
ABCB1 NC_000007.14:g.87509329A>G rs1045642 AA Unclear** [76, 77]
ABCC1 NC_000016.10:g.16144637G>A rs4148382 GG Improved six month out-
comes (GOS* Scores)
[76]
ABCC8 NC_000011.10:g.17440757A>C rs2283261 CC Higher risk for cerebral
edema
[78]
NC_000011.10:g.17465190C>T rs3819521 TT Higher risk for cerebral
edema
[78]
NC_000011.10:g.17451890C>T rs2283258 TT Higher risk for cerebral
edema
[78]
ADK NC_000010.11:g.74683339A>G rs11001109 GG Increased seizure dura-
tionshorter time to first
seizure
[79]
ADORA1 NC_000001.11:g.203163914A>G rs3766553 AA Higher risk for post-
traumatic seizures
[47]
NC_000001.11:g.203139380T>C rs10920573 CT Higher risk for post-
traumatic epilepsy
[47]
NC_000001.11:g.203163914A>G rs3766553 AA Higher risk for post-
traumatic epilepsy
[47]
ANKK1 NC_000011.10:g.113400106G>A rs1800497 GA Higher composite cogni-
tive score
[80]
APOE Epsilon 4 NA ε4/ε4 Higher risk for post-
traumatic seizures
[51, 52]
AQP4 NC_000018.10:g.26855854C>T rs3763043 TT Unfavorable six month
outcomes (GOS* Score)
[81]
NC_000018.10:g.26865469T>C rs3875089 CT;CC Poor six month out-
comes (GOS* Score)
[81]
COMT NC_000022.11:g.19963748G>A rs4680 GA;GG Higher risk for cognitive
decline
[82, 83, 84, 85]
DRD2 NC_000011.10:g.113410351G>C rs6279 GG;GC Higher composite cogni-
tive score
[80]
GAD1 NC_000002.12:g.170826230C>T rs3828275 TT Higher risk for post-
traumatic seizures
[50]
NC_000002.12:g.170852920A>G rs769391 AA Higher risk for post-
traumatic epilepsy
[50]
NC_000002.12:g.170815681G>T rs3791878 GG Higher risk for post-
traumatic epilepsy
[50]
IL-1β NC_000002.12:g.112832813G>A rs1143634 AG Higher risk for post-
traumatic epilepsy
[86]
MTHFR NC_000001.11:g.11796321G>A rs18001133 TC;TT Higher risk for post-
traumatic epilepsy
[87]
NT5E NC_000006.12:g.85465856G>A rs9444348 GA Increased seizure dura-
tionshorter time to first
seizure
[79]
SLC1A1 NC_000009.12:g.4557296C>G rs10974620 GG Higher risk for post-
traumatic epilepsy
[88]
SLC6A4 5-HTTLPR NA Long/Long Higher risk for post-
traumatic depression
[89]
VMAT2 NC_000010.11:g.117265701G>C rs363226 GC;GG Higher risk for cognitive
decline
[90]
HG38: Human Genome Version 38; **: Conflicting data; NA: Not Applicable
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tients and to select appropriate pharmacotherapy early post TBI.
1.2.2.2 Post-Traumatic Cognitive Decline
Post-traumatic cognitive decline is common in patients with severe TBI and is thought
to be driven by white matter loss (i.e. progressive damage to axonal tracts) and
hippocampal atrophy.[94] While some patients’ cognitive function improves in the
immediate year following TBI, over five million Americans suffer from life-long pro-
gressive cognitive decline from TBI.[94] Genetic predictors may provide insight into
the heterogeneity for risk and severity of cognitive decline.[29] They may also pro-
vide insight into what patients will benefit from early treatment. Effective pharma-
cotherapy for cognitive decline from TBI is not currently available and its develop-
ment presents unique challenges. This is evident by a Cochrane review by Dougall
and colleagues, which concluded that there is insufficient evidence for the effec-
tiveness of pharmacotherapy for cognitive decline post TBI, however; their inclusion
only evaluated modafinil, atomoxetine, rivastigmine, and an investigative monoamine
modulator.[95] Additional study into other agents for cognitive decline is warranted.
Failla and colleagues evaluated the role of the dopamine receptor D2 gene (DRD2)
and its genomic neighbor; ankyrin repeat and kinase domain containing 1 (ANKK1)
in 99 Caucasians with severe TBI. They found that DRD2 rs6279 (GG,GC) was asso-
ciated with higher (improved) composite cognitive score at six months and ANKK1
rs1800497 (GA) was associated with higher composite cognitive score at six and 12
months post TBI.[80] Wagner and colleagues investigated the role of the WW domain-
containing protein (WWC1) in 129 patients with severe TBI for its impact on mem-
ory. They found that WWC1 rs17070145 (CC) was associated with improved perfor-
mance on episodic memory tests.[96] The rs363226 (GC,GG) genotypes in the vesic-
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ular monoamine transporter 2 gene (VMAT2) was identified by Markos and colleagues
to be associated with increased risk for cognitive decline as measured by cognitive-
composite T scores. VMAT2 takes up monoamine neurotransmitters from the cytosol
to vesicles, where they are stored for later release into the synapse.[90] In Catechol-
O-methyltransferase (COMT) rs4680, the (GA,GG) genotypes are associated with nu-
merous cognitive impairments after TBI, including worse nonverbal cognitive perfor-
mance, PTSD, worse self-reported behavior among survivors with PTD, and worse ex-
ecutive functioning in pediatric TBI.[82, 83, 84, 85]
Beyond its utility as a predictor of outcomes, variations in dopamine pathways
are associated with response to stimulants, anti-psychotics, and others.[97] Phar-
macotherapy with methylphenidate has shown benefits for post-TBI cognitive impair-
ment, and increased knowledge of how genetics influences various elements of cogni-
tive performance that are amenable to improvement with a particular pharmacological
intervention may guide cognitive testing, medication selection, and follow-up and care
post-injury.[98]
1.2.2.3 Post-Traumatic Epilepsy
Post-Traumatic Epilepsy is defined by the occurrence of unprovoked seizures that occur
seven days or more after TBI. The five year risk for PTE is 11.5% for people with severe
TBI, and 1.6% for those with moderate TBI.[75] Genetic markers may predict risk for
PTE and guide therapeutic decisions. Diamond and colleagues evaluated both Inter-
leukin 1β (IL-1β) levels and associated genetic variations in the IL-1β gene with risk for
PTE development. They found that the IL-1β rs1143634 (AG) genotype was associated
with nearly three-fold increased risk or PTE and higher cerebro-spinal fluid (CSF)/serum
ratios of IL-1β.[86] The methylenetetrahydrofolate reductase (MTHFR) gene has been
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investigated for its role in epilepsy, including PTE, as MTHFR dysfunction can lead to
elevated homocysteine and lowered seizure threshold.[99, 87] Scher and colleagues
investigated the role of MTHFR in a population of from the armed forces with evidence
of epilepsy diagnosis and history of TBI. They found that MTHFR rs18001133 (TC,TT)
genotypes were associated with higher risk for PTE when they limited their population
to subjects with two or more encounters for epilepsy (Adjusted Odds Ratio: 2.55).[87]
Similar to the associations of the adenosine pathway and PTS, ADORA1 rs10920573
(CT) and rs3766553 (GG) are associated with increased risk for PTE.[47] Also in that
pathway; adenosine kinase (ADK) rs11001109 (GG), and ecto-5’-nucleotidase (NT5E)
rs9444348 (GA) are associated with increased seizure duration and shorter time to
initial seizure in patients who develop PTE.[79] In addition to their work in PTS, Darrah
and colleagues found that GAD1 rs769391 (AA) and rs3791878 (GG) were associated
with PTE risk between one to six months post TBI.[50] Ritter and colleagues found
that SLC1A1 rs10974620 (GG) and rs7858819 (TT) were associated with higher risk
for PTE.[88]
The use of genetic markers to predict incidence of PTE may help clinicians monitor
and treat patients with PTE more effectively. Importantly, prophylactic treatment with
anti-epileptic drugs does not reduce the incidence of PTE.[100] Genetic variations
may have contributed to failure of randomized controlled trials and may have a role
in supporting future drug development. PGx may also have similar application to the
long-term use of phenytoin in relation to CYP2C9 metabolizer status, or the decision
to not use it based on presence of HLA-B*57:01.[37, 38]
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1.3 PHARMACOGENOMICS-GUIDED DRUG DEVELOPMENT
Drug development for TBI has focused on better understanding of the variables most
associated with response. These include biometric measures (e.g. height, weight,
age), type of injury, co-occurring diseases, and genetic factors. Evaluating genetics of
TBI in association with disease progress and clinical outcomes has identified numerous
areas for targeted drug development.[29, 101] In the very active area of TBI drug
development, many efforts have focused on the prospect of drug re-purposing, often
a much more affordable and easily translated approach.[31] This approach allows for
fast clinical translation due to the decreased need for pre-clinical development and
safety trials.[31]
1.3.1 Sulfonylurea Medications
Development of cerebral edema occurs in nearly half of patients with severe TBI, par-
ticularly in patients with computerized tomography (CT) evidence of mass lesion.[102]
Prevention and treatment strategies include decompressive craniectomy, decreasing
ICP through CSF drainage, and/or hyperosmolar therapy with mannitol or hypertonic
saline.[12] The ATP-binding-cassette, subfamily C, member 8 (ABCC8) has received at-
tention recently due to its association with the transient receptor potential melastatin
4 (TRPM4) specifically in the traumatically-injured brain. TRPM4 permits the transcellu-
lar flux of Na+, which leads to ionic edema (i.e. driven by fluid high in sodium and low
in protein). ABCC8 regulates TRPM4 by closing the channel when intracellular ATP is
high.[103] The ABCC8 antagonist, glyburide (glibenclamide), is thought to prevent the
opening of the ABCC8-TRPM4 channel post-TBI. It is under investigation as a treatment
for cerebral edema post TBI, has been successful in pre-clinical studies, has shown
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promise in clinical trials in stroke, and is currently in phase II clinical trials for preven-
tion of CE in moderate/severe TBI (clinical trials identifier: NCT01454154).[31, 104]
Jha and colleagues studied ABCC8 with a candidate gene approach for risk of de-
veloping cerebral edema (CE) post severe TBI. They found significant associations
with rs2283261 (CC), rs3819521 (TT), and rs2283258 (TT) in the ABCC8 gene with
increased risk of CE following severe TBI (OR: 2.45, 2.95, and 3.00, respectively).[78]
This finding suggests a genomic role wherein ABCC8 PGx may help predict the occur-
rence of CE, and may help guide the appropriate use of glyburide in the intensive care
unit. An additional contributor to risk for CE post-TBI is Aquaporin-4 (AQP4).[105] Dar-
diotis and colleagues investigated the role of AQP4 with clinical outcomes following
TBI and found that AQP4 rs3763043 (TT) and rs3875089 (C) were associated with a
higher odds of having an unfavorable and favorable six-month GOS scores, respec-
tively, which suggests that a molecular moderator of CE risk (AQP4) impacts TBI
outcomes.[81] These findings support the important role of pharmacologically pro-
tecting from CE in TBI patients. Glyburide, among other sulfonylurea medications, is
also metabolized by the polymorphic CYP2C9.[37] While there are no current clinical
recommendations regarding dosing when used as an anti-diabetic agent, glyburide is
given at a sub-therapeutic dose in TBI relative to its FDA-approved dosing for diabetes.
Hypoglycemia is undesirable post TBI, and it is possible that CYP2C9 poor/intermedi-
ate metabolizers may be more likely to develop hypoglycemia.[103, 37]
1.3.2 Modulation of CNS Metabolism
Cytochrome p-450 enzymes (CYPs) are also present in the brain and in the cerebro-
vascular endothelium.[106] Little has been investigated regarding the role of genet-
ics of brain-specific CYPs, but Donnelly and colleagues investigated CYP polymor-
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phisms in patients with subarachnoid hemorrhage (SAH). They found that CYP4A11
rs9332978 (CT,CC) was associated with decreased CSF of the cerebral vasoconstrictor,
20-hydroxyeicosatetraenoic acid (20-HETE). Results also showed that the GG geno-
type at rs3093089 in the CYP4F2 gene was associated with decreased risk for clinical
neurologic deterioration. Finally, they found that CYP4A11 rs3890011 (GC,CC), CYP4F2
rs3093156 (TA,TT), and CYP4F2 rs3093168 (AA) were associated with higher odds of
having a favorable outcome.[107] Further Investigations are needed to delineate how
brain specific CYPs affect drug disposition in the context of TBI. This area has been an
important focus in drug development for SAH and may be an area of drug develop-
ment for TBI with evidence of hemorrhage.[107]
1.3.3 CNS Antioxidants
Oxidative stress drives the secondary injury early post-TBI, and brain antioxidant re-
serve is depleted after severe TBI.[108, 109] CNS antioxidant use has been under
investigation as a treatment strategy for TBI. N-Acetylcysteine is an FDA approved
medication that is under investigation as a therapy for TBI to increase the brain con-
centration of glutathione (GSH), a potent CNS antioxidant.[31] Due to its hydrophilic-
ity and poor penetrance through the BBB, it also is being investigated in combination
therapy with the SLC22A6 and SLC22A8 inhibitor, probenecid.[110] This strategy has
been shown to increase brain concentrations of NAC in pre-clinical studies, and might
increase its efficacy.[111]
22
1.4 THE ROLE OF TRANSPORTER PROTEINS IN TRAUMATIC BRAIN INJURY
Previous sections have discussed the roles of diverse genes that are related to TBI
recovery, outcomes, and complications. Transporter genes are of particular inter-
est post TBI because 1) they support the movement of helpful and toxic solutes in
and out of the brain and 2) their impact in either facilitating or blocking the entry
of medications into the brain.[112] These are loosely defined in two super-groups,
the ATP-Binding Cassette (ABC) transporters and the solute-carrier (SLC) transporters.
The ABC transporters are exclusively dependent on ATP hydrolysis to transport solutes
from the intracellular space to the extracellular space, often counter to concentration
gradients.[112] Depending on localization, they may move solutes across apical or
basolateral membranes. The SLC transporters are more frequently dependent upon
concentration gradients of co-substrates, often sodium gradients. They are most of-
ten uptake transporters, but some are efflux or bi-directional.[112] Both classes of
transporters are drivers of active transport throughout the body and are critical to the
maintenance of concentration gradients.
1.4.1 Transporters as Mediators of Traumatic Brain Injury
Transporters are expressed on the BBB, blood-CSF barrier, neurons, and microglia.
They mediate the entry of impermeable substrates, and move toxic substrates from
the CNS to the blood so that they can be eliminated.[113] Recent work has demon-
strated that genetic variation in transporters are associated with outcomes follow-
ing TBI. Cousar and colleagues investigated genetic variations in BBB transporters
(ABCB1, ABCC1, and ABCC2) in 305 adult patients with severe TBI. They found that
ABCB1 rs1045642 (AA) and ABCC1 rs4148382 (GG) genotypes were associated with
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lower odds of unfavorable six month Glasgow Outcome Scale (GOS) scores, defined
as GOS of 1-3 (Odds Ratio: 0.71 and 0.73, respectively).[76] The finding with ABCB1
rs1045642 was reversed in a study by Wang and colleagues who studied 182 patients
with TBI. They defined favorable outcomes as GOS of 3-5 and found that patients with
the (AG,GG) genotypes were more likely to have favorable GOS scores at six months
post TBI (Odds Ratio: 2.71)[77] These contradictory results may be due to different
definitions of outcomes and/or racial composition (i.e. Caucasian vs. Asian). The
ABC transporter, ABCG2, is closely related to ABCB1 and ABCC1 and is also highly
expressed in the CNS. ABCG2 has not been studied in the context of TBI, but its role
in removing substrates that may be relevant to pathophysiology in TBI (e.g. protopor-
phyrin IX and uric acid) suggest that it may play a similar role post TBI as ABCB1 and
ABCC1.[114]
The discovery of ABCG2 was published in 1998 by Doyle and colleagues after it
was found in the MC-7 breast cancer cell line as a contributer to efflux of anthracycline
chemotherapeutic agents.[115] It was aptly named breast cancer resistance protein
and investigated for its role in chemotherapy resistance in many cancers.[115] This led
to investigations into the use of xenobiotics that inhibit ABCG2 as adjunctive cancer
therapy in addition to chemotherapy.[116] A similar strategy has been employed for
other transporters with roles in drug resistance. Targeted pharmacologic modification
of transporter function in the brain may be therapeutic for TBI. This is exemplified by
the work by Hagos and colleagues by using the transporter inhibitor, probenecid, to
promote brain concentrations of N-Acetylcysteine.[111]
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1.4.2 Knowledge Gaps for Transporters in TBI
Despite the growing body of literature suggesting that transporters are relevant and
important to brain recovery post TBI, little is known about what drives these indi-
vidual effects. Answering these questions requires a focused approach that targets
individual transporters of interest with a focus on mechanistic relationships with TBI
pathophysiology and recovery. These can be studied in a clinical/translational man-
ner by investigating transporter response to injury in experimental TBI (e.g. gene
expression), measuring clinical outcomes in relation to functional genetic variation in
transporters, and studying the impact of transporter dysfunction on substrate disposi-
tion. Very little is known about how transporter gene expression changes after TBI in
various brain tissues. Study into this area would complement investigations into the
association of functional transporter variations with injury, thus providing a reasonable
pathway into new drug development pathways and clinical translation.
1.4.3 The Role of ABCG2 Following TBI
The ABC transporter, ABCG2, is of particular interest within the area of neurologic
disease due to its high level of expression in the brain and potential role in removing
xenobiotics and endogenous substrates from the brain.[117] It is highly expressed
in humans and animals and has roles in maintenance of endogenous substrates and
xenobiotics. ABCG2 is also polymorphic, with high frequency functional variations that
are conducive to clinical study.[118, 119]
1.4.3.1 ABCG2 Regulation, Structure, and Function
The ABCG2 gene spans approximately 66 kilobases with 16 exons.[120] The pro-
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moter region begins approximately 400bp upstream from the first exon, which lacks
TATA and CCAAT boxes.[120] This ABCG2 promoter region contains contains multiple
binding sites for the SP1, SP3, AP1, AP2, and XBBF transcription promoters.[120] Up-
stream transcription regulation for ABCG2 is driven by the Aryl Hydrocarbon Receptor
(AHR),[121] the hypoxia-inducible factor complex 1 (HIF-1)[122], the estrogen recep-
tor (er),[123] nuclear factor erythroid 2-related factor 2 (NFE2L2),[124] peroxisome
proliferator-activated receptor gamma (PPARγ)[125], and the progesterone receptor
(PR).[126] Baseline expression of ABCG2 is likely maintained by activation of AHR, and
induced in the presence of environmental toxicants.[127] This is particularly noted in
the induction of AHR by tobacco smoking, which induces the transcription of CYP1A2
and ABCG2.[127] This suggests that increased ABCG2 transcription is beneficial in the
presence of environmental toxicants.[127]
Inhibition of ABCG2 expression on the BBB is associated with cytokines, particularly
interleukin-6 (IL-6), interleukin 1 beta (IL-1β), and tumor necrosis factor alpha (TNF-
α).[128] MicroRNAs 200c, 212, 328, 519, and 520 have also been found to inhibit
expression of ABCG2.[129] The precise mechanism by which cytokines inhibit expres-
sion of ABCG2 mRNA has not been fully elucidated. The mechanism for inhibition of
ABCG2 transcription from cytokines is likely not related to the JAK/STAT downstream
pathway from IL-6, as the ABCG2 gene does not contain the binding site.[120] Cy-
tochrome P-450 expression inhibition by IL-6 is driven by the downstream transcription
factor C/EBPβ-LIP, but this binds the CCAAT box, which is not present on the ABCG2
gene.[130, 131] This suggests a more indirect link between cytokine signaling and
inhibition of ABCG2 gene expression.
The ABCG2 protein is a 72-kDA membrane transport protein that is phylogenet-
ically related to other ABC transporters, most closely ABCG1 and only distantly re-
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lated to ABCB1.[132] The "G" family of ABC transporteres are referred to as reverse
transporters due to the reversed positioning of the nucleotide binding domain with re-
spect to the N-terminus.[132] ABCG2 is expressed as a half transporter and is thought
to form homo-oligmers in order to properly function.[133] ABCG2 effluxes a diverse
range of substrates including xenobiotics; uric acid (UA); and porphyrins, such as pro-
toporphyrin IX. Within the brain, ABCG2 is expressed in endothelial cells of the BBB,
ependymal cells of the blood-CSF barrier, microglia, and neurons.[134, 135] On the
BBB, it is expressed on the apical membrane and faces blood removing its substrates
from the brain compartment, thus playing a primary role in both limiting CNS expo-
sure and removing molecules generated within the CNS .[134] This directionality is
reversed on the blood-CSF barrier, where it faces CSF on choroid plexus ependymal
cells.[135] This suggests a potential inverted relationship between the concentration













Figure 1.2: ABCG2 protein expression is blood (red) facing on the blood brain barrier
(right) and CSF facing on the bood-CSF barrier (left). ABCG2 substrates may exhibit
an inverse relationship with respect to ABCG2 expression changes in the CSF versus
the brain.
1.4.3.2 ABCG2 Genetic Variation
Common functional genetic variations in the ABCG2 gene are found in most popu-
lations. Minor allele frequencies (MAFs) for the non-Finnish European population as
reported in the gnoMAD browser are used throughout this project.[136] Two missense
variations are particularly, including rs2231137 (c.34G>A, p.Val12Met, MAF=0.0409)
and rs2231142 (c.421C>A, p.Gln141Lys, MAF=0.1036).[136] Extensive work by Tamura
and colleagues has found that the c.421C>A variation is associated with normal mRNA
expression and decreased protein expression.[119] They also found that c.34G>A is
associated with normal mRNA and protein expression and possibly increased trans-
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porter function, as measured by survival of transfected cells treated with cytotoxic
substrates of ABCG2.[119] The presence of two common and functional variations
that can predict both increased and decreased transporter activity/function provide
an ideal scenario for studying the role of ABCG2 following TBI.
1.4.3.3 ABCG2 and Uric Acid in Neurologic Disease
The c.421C>A variation in the ABCG2 gene is of particular interest in neurologic dis-
eases due its impact on the transport of UA. Individuals who carry at least one "A"
allele have higher risk for hyperuricemia and gout due to decreased renal elimination
of UA.[137] Uric acid is interesting on its own due to its role as an antioxidant, and
that has led to substantial interest in studying the role of rs2231142 and UA in neu-
rologic diseases associated with increases in oxidative stress. Matsuo and colleagues
investigated rs2231142 in in patients with Parkinson’s disease and found that patients
carrying at least one variant allele developed Parkinson’s disease later, suggesting a
protective effect.[138] UA alone has also been implicated as a protective agent against
Lewy Body Dementia.[139] Feher and colleagues noted similar findings in Alzheimer’s
disease, where the variant "A" allele was protective against the disease.[140] It is not
known if c.34G>A is associated with an opposing effect on UA transport or disease
risk.
1.5 CONCLUSION
Traumatic brain injury research is aimed at attaining better understanding of the dis-
ease processes and developing novel treatments. The use of PGx to support drug de-
velopment has also been supported by the myriad genetic association studies, which
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have identified several common genetic variations that are associate with disease.
Associations between genetic variation in transporter genes and TBI outcomes has
highlighted the growing role for transporters as markers of disease and targets for
treatment.
The work described in this dissertation focuses on the role of transporters in TBI.
We are interested in the potential association of genetic variations in the ABCG2 gene
in patients suffering from severe TBI. Furthermore, we seek to further explain changes
in brain chemistry that occur as a result of severe TBI within the pediatric and adult
brain.
1.6 HYPOTHESIS
The current knowledge of TBI with respect to transporters suggests that several genes
that are already understood to impact drug disposition might have a role in recovery
following TBI. This generates further interest because these are already under inves-
tigation for their role in cancer drug resistance and drug-drug interactions. We are
particularly interested in studying the disposition of transporters following injury, and
specifically focusing on the role of the ABC transporter, ABCG2, due to its potential
role in removing cytotoxic porphyrins and UA from the brain.
The objective of this work is to determine the genetic and molecular role of the
transporter, ABCG2, following severe TBI. We hypothesize that 1) transporter expres-
sion is globally stunted following severe TBI due to increase in inflammatory cytokines
and 2) decreased function of ABCG2 as predicted by genetic variation is associated
with improved clinical outcomes following severe TBI due to increased CNS concentra-
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tion of UA. These hypotheses are tested in the following aims:
Aim 1: Measure the Timing and Magnitude of Transporter Expression Changes Follow-
ing Experimental Traumatic Brain Injury
This study will investigate the time-dependent changes in transporter expression in
experimental TBI. It will utilize a pre-clinical model of pediatric severe TBI.
Aim 2: Evaluate the Role of ABCG2 genetic variation on Clinical Outcomes Following
Severe TBI
This aim will consist of a retrospective clinical cohort (discovery and replication) trial
evaluating the impact of genotype on longitudinal outcomes.
Aim 3: Measure the Impact of Uric Acid Disposition on Clinical Outcomes Following
Severe TBI
This study will evaluate the levels of UA in the CSF and plasma in patients with severe
TBI in contrast to TBI outcomes and ABCG2 genotype. It will utilize a subset of the
subjects sampled in aim 2.
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Growing knowledge of TBI suggests that transporters are relevant prognostication and
treatment targets. However, little is known about how the changes following TBI im-
pact transporter expression. In this section, we sought to determine the timing and
magnitude of expression changes in transporters following TBI.
2.1.1 Role of the CNS Barriers in Traumatic Brain Injury
Key to the progression of secondary injury are changes in the BBB, blood-CSF barrier,
and permeability of neurons and microglia. This is driven by physical changes from
injury, complex biochemical perturbations, which include changes in expression of
transporters on the BBB and within the brain.[26, 141] This change in transporter
expression changes the brain’s ability to uptake nutrients, remove toxins, and may
have substantial effect on the flux of pharmacological agents across the BBB, neurons,
and microglia.
2.1.2 Previous Studies of Transporters and Gene Expression in TBI
Traumatic brain injury has dramatic effects on the neuro-chemical milieu, with varying
directionality and magnitude depending on the time following the primary injury.[54]
An investigation by Willyerd and colleagues investigated protein expression for the
ATP-Binding cassette transporters ABCB1 and ABCC1 in post-mortem human brain tis-
sue and found that ABCC1 protein levels in cortex of injured subjects was higher than
control, and that ABCB1 showed little change.[141] However, this study combined
diverse sampling times (based on time from injury) that is not able to comprehen-
sively evaluate temporal differences in expression. Transcriptomic profiling post TBI
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has been carried out by Di Pietro, et al. using a stretch model for TBI in organotypic
hippocampal slice cultures. They identified several pathways involved in secondary
injury that were associated with inflammation and cytokines.[142] These findings sug-
gest that transporter expression changes due to the pathophysiology of TBI, and that
those changes may be important to understanding the progression of secondary injury
after TBI.
2.1.3 Objective and Hypothesis
Little is known about the directionality, timing, and magnitude of transporter expres-
sion changes in the pediatric brain. Answering these questions will increase the under-
standing of secondary injury and will aid in the identification of molecular targets for
secondary injury.[143] There is also limited information regarding the relative levels
of the expression of different transporters at baseline in the pediatric brain and poor
understanding of the changes associated with development. We sought to 1) develop
a targeted panel of transporter genes in the brain, 2) determine baseline relative
transporter expression in pediatric and adult rats, 3) determine the magnitude and
timing of expression changes following experimental TBI, and 4) correlate changes
in transporter expression with activated pathways. We hypothesized that transporter
mRNA expression would be decreased following experimental TBI in conjunction with
enrichment of pathways associated with inflammation and hypoxia.
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2.2 METHODS
2.2.1 Gene Expression Panel
We developed a targeted panel of transporters of potential relevance to pathophysi-
ology of secondary injury and/or drug development. First, we conducted a literature
review to identify transporters, biomarkers, and transcription factors that were of prob-
able importance to TBI pathophysiology. This was judged based on 1) expected ex-
pression in the brain, 2) previously noted roles in brain disease, and 3) role in transport
for medications used in TBI. Next, we added transporters that are recommended for
evaluation in the context of drug-development by the International Transporter Con-
sortium and FDA guidelines.[144] Biomarkers and transcription factors were added to
the panel based on 1) evidence for a role in TBI and 2) data supporting their role in
modulating expression of genes related to metabolism. Finally, those human genes
were transposed to their corresponding rat homologues by using the NCBI Homolo-
Gene. Housekeeping genes were selected based on evidence for stability post TBI.
The final list of genes was developed into a custom panel for quantitation of mRNA
using the nCounter® (NanoString Technologies, Seattle, WA) platform. This technol-
ogy allows for the absolute quantitation of transcripts using barcoding, which enables
deeper comparisons between genes and tissues.
2.2.2 Animal Husbandry
All animal experiments were performed in accordance with the University of Pittsburgh
Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (Charles
River, Wilmington, MA) were used for this experiment. Rats were housed in a temper-
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ature (22°C) controlled room with a 12h light/dark cycle and allowed access to water
and chow ad libitum during the experiment, and were weighed daily. Seventy-two
post natal day (PND) 17 rats were randomized 2:1 to experimental TBI and sham in-
jury. Eight PND 17 rats and four adult rats (300g) remained naïve to injury for a total
of 84 rats. Animal groupings and time of sacrifice were randomized a priori to control
for litter effects.
2.2.3 Experimental TBI
Experimental TBI was carried out using the controlled cortical impact (CCI) model.[145]
Rats were anesthetized with a 2:1 mixture of N2O:O2 with 4% isoflurane for induction
and 2% for maintenance through a nosecone. Continuous rectal temperature was
measured and maintained at 37°C using a heated pad. The head was secured using a
stereotaxic frame with ear pins. The scalp was shaved and prepared with a betadine
swab. Using sterile aseptic technique, a mid-line sagittal incision was made followed
by reflection of the scalp with retractors. A high speed air-powered dental drill was
then used to make a 7mm craniotomy in the left parietal bone, which was removed
to expose the dura. A calibrated pneumatic piston was then used to impact the intact
dura with a 2.5mm deformation and impact velocity of 4m/s. Sham injured animals
received the full procedure with the exception of the impact.
2.2.4 Dissection
CCI and sham rats were sacrificed at 3, 12, 24, 72, 168, and 336h post-surgery. Naïve
PND 17 rats were sacrificed at PND 17 and at PND 31. Adult rats were sacrificed
upon arrival to our facility. All work surfaces and surgical tools were cleaned with
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RNaseZap® (Thermo Fisher Scientific, Waltham, MA) before each procedure. Rats
were placed in a plastic chamber and subjected to 4% isoflurane and 2:1 N2O:O2 for
induction of anesthesia. Once anesthetized, rats were transferred to an absorbent
pad and affixed with a nosecone providing 2% isoflurane with 2:1 N2O:O2 for mainte-
nance of anesthesia. Following cardiac puncture and withdraw of blood (for plasma),
rats were decapitated, and the brain was extracted and placed on an inverted glass
petri dish on a bed of wet ice. Blood was injected into a 1.5mL microcentrifuge tube
pre-loaded with 5μL of heparin, then centrifuged at 2500G for 5 minutes, then the
plasma was pipetted into a fresh microcentrifuge tube and immediately frozen on liq-
uid nitrogen. The brain was rinsed gently with ice cold normal saline frequently during
dissection. The ipsilateral and contralateral cortices were removed first, followed by
the ipsilateral and contralateral hippocampi. Finally, the choroid plexus was removed
with pointed, curved forceps. After processing the brain, the abdomen was dissected
and a single kidney was removed and an approximately 50g section of liver tissue
was removed. Each tissue sample was placed in a separate, pre-labeled microcen-
trifuge tube, then immediately frozen with liquid nitrogen and later stored at -80°C
until further processing.
2.2.5 Isolation and Analysis mRNA and Protein
This study also presented an opportunity to build a repository of animal tissue for
future study. As such, we were interested in methods that facilitated high quality sam-
ple collection, storage, and processing. These methods are summarized below and




To facilitate current and future applications of the tissue collected from this study,
we sought to develop a method to obtain high quality RNA and protein. Initially,
we employed a method suggested by a Qiagen supplementary protocol, which sug-
gested using 4 volumes of ice-cold acetone to the initial RNeasy column filtrate, cen-
trifuging, then reconstituting.[146] This was initially tested using brain tissue from a
previous rat study for the integrity of the protein. We compared protein collected
through acetone precipitation with crude cell lysate loaded on an sodium-dodecyl-
sulfate poly-acrylamide gel electrophoresis (SDS-PAGE), then with western blotting.
We used Abcg2 antibody as a probe given that previous experience in our lab showed
that antibody affinity for Abcg2 protein is sensitive to sample processing. The ace-
tone precipitation sample showed strong signal for the β-actin band, but a virtually
absent Abcg2 band. The lysate western blot showed strong signal for Abcg2 and
β-actin, suggesting that Abcg2 was either lost in the acetone precipitation step, or
that the other chemicals involved in the Qiagen RNeasy procedure caused sufficient
damage to the Abcg2 protein to prevent the antibody from binding. Finally, we devel-
oped a compromise method in which microcentrifuge tubes containing frozen whole
tissue (hippocampus, cortex, choroid plexus) were filled with an aliquot of radioim-
munoprecipitation assay (RIPA) buffer containing 1% v/v beta-mercaptoethanol and
homogenized using a hand-held homogenizer. A 150μL aliquot of the homogenate in
RIPA buffer was used in place of the typical starting material in the manufacturer’s
protocol. We tested the quality of mRNA in this procedure as well using a bio-analyzer
to ensure that mRNA was not damaged in the modified procedure Figure 2.1A. The
remaining homogenate was frozen at -80°C and was evaluated with SDS-PAGE and









Figure 2.1: Results of western blotting and bioanalyzer to verify protein and mRNA
quality. Figure 2A depicts a representative plot of bioanalyzer output for mRNA
collected through our modified Qiagen protocol. Few small peaks and sharp peaks at
the 18s and 23s ribosomal subunits suggest that mRNA is relatively intact (i.e. high
quality). Figure 2B depicts a crude western blot verifying the presence of
antibody-targetable Abcg2 and beta-actin protein.
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2.2.5.2 Tissue Processing and mRNA Isolation
mRNA was isolated from tissues using a modified version (see previous section) of
the manufacturer’s protocol with the RNeasy Mini Kit (QIAGEN, Hilden, Germany). For
liver and kidney, the standard Qiagen procedure was used after manually homoge-
nizing the liver and kidney tissue with a mortar and pestle while frozen at -80°C. Ap-
proximately 30g of the pulverized liver and kidney was used for mRNA isolation with
the remaining placed in a microcentrifuge tube and frozen at -80°C. For the choroid
plexus, we also used the standard Qiagen procedure and loaded th entirety of the
tissue collected into the microcentrifuge tube for homogenization. RNA quality and
concentration were assessed with NanoDrop (Thermo Fisher Scientific, Waltham, MA).
2.2.6 Measurement of mRNA Expression with Nanostring
2.2.6.1 Selection of Samples
Samples were selected based on 1) previously planned sample inclusion and 2) extra
slots available on gene expression panel that could potentially answer supplemen-
tary questions. Pre-determined tissues include 1) naïve hippocampus and cortex in
PND 17, PND 31, and adults; 2) naïve choroid plexus, liver, and kidney in PND 17
and PND 31; and 3) all sham and CCI ipsilateral hippocampus and cortex. Due to an
additional availability of nine slots on the plate, a subset of four CCI rats had mRNA
expression measured in the contralateral hippocampus, and five contralateral cortex
from the 24h post-CCI time point. The samples were then diluted with RNase/DNase
free water to a concentration of 30ng/μL to satisfy the 3μL loading volume for Nanos-
tring with a goal starting amount of approximately 100ng mRNA. mRNA quantification
was conducted using the manufacturer’s instructions for Nanostring. Briefly, capture
probes with a biotinylated tail and reporter probes with a fluorescent barcode com-
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plementary to target transcripts are hybridized with 100ng of each sample at 65°C
overnight, then loaded on the Prep Station®, which is an automated liquid handler
that removes excess sample and unbound codesets in a two-step bead clean-up pro-
tocol. After purification, probe/transcript complexes are eluted and transferred to the
streptavidin coated nCounter® cartridge, which binds the biotinylated region of the
probe/transcript complex. Next, a current was applied to align the reporter probes.
The cartridge was then scanned with a Digital Analyzer, which scans 600 fields of
view across each cartridge and counts the occurrence of each fluorescent barcode.
Digital counts are then reported for normalization and analysis.
2.2.7 Statistical Methods
Data normalization and summary statistical analyses were carried out using R v3.4.3
(R Development Core Team, Vienna, Austria).
2.2.7.1 Nanostring Data Normalization
Raw transcript counts were obtained from the nCounter® platform and normalized
with the R package NanoStringNorm. The variation was assessed for all possible com-
binations of normalization parameters using the following code.
require(NanoStringNorm)
RCC_Files <- read.markup.RCC(rcc.path = "RCC/") #Reads files
compare_norms <- norm.comp(RCC_Files) #Compares normalization methods using
signal to noise
To remain conservative, we did not utilize the "OtherNorm" options for normalization,
which include variant stabilization and normalization for micro-array data (VSN), z-
score normalization, or quantile normalization. While these methods can further opti-
mize the variance, they are not well documented or accepted for Nanostring data. We
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also opted, based on the default normalization method, to limit to geometric mean for
the code-count normalization with a strategy of minimizing the variance in code count,
housekeeping, and end result variation. Despite not minimizing the variance, we used
the mean alone, rather than the mean plus two standard deviations as the correction
for background noise. This provides a more liberal consideration for whether signal
is from actual mRNA or from noise (i.e. fewer samples considered zero expression).
This was due to the high quality mRNA provided, relatively few mRNA targets, and
expectation that all, or almost all, of the targets would be present in each sample.
The normalization parameters, as coded, are demonstrated in the following code.
Data_Norm <- NanoStringNorm(RCC_Files,
CodeCount = "geo.mean",
Background = "mean", #Note that mean.2sd provides







Samples with a background value greater than three standard deviations from the
mean were re-run if possible, or excluded from further analysis. Following normal-
ization, all counts were log2 transformed for downstream analysis. These steps were
separated for all tissues evaluated (i.e. cortex, hippocampus, liver, kidney, choroid
plexus). Analyses were completed in two sets in 2015 and 2017, with slight modifica-
tions to the panel in 2017. This required separate normalization for tissue batches that
were then merged. Normalization findings for variation compared across methods are
included in Appendix A.
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2.2.7.2 Analysis of Naïve Data
Counts from naïve animals at PND 17, PND 31, and adults in hippocampus and cortex
were measured to determine differences associated with development. Data for PND
17 and 31 was also measured in choroid plexus, liver, and kidneys. For all tissues,
relative expression compared to liver and kidneys was evaluated and presented as:
ƒ (, y) = log2() − log2(y);
where  and y are expression in the relevant brain tissue and liver or kidney, respec-
tively. All pairwise comparisons for naïve data were not performed due to the volume
of data that would be produced. Count data are presented as raw counts and as rela-
tive expression to liver and kidney. Raw count data for all naïve tissues are presented
in Appendix A, Tables A3 and A4.
2.2.7.3 Analysis of CCI v. Sham
To measure changes associated with injury, transcript counts in the ipsilateral hip-
pocampus and cortex were compared with sham animals at each time point with un-
paired t-tests. Counts for injured rats were compared with sham rats at each time
point for fold change. Fold change P values were corrected using Benjamini-Hochberg
False Discovery Rate (FDR) to produce q values.[147] For all analyses, a q-value of
0.05 was considered statistically significant. To identify enriched disease pathways
and upstream regulators, log2 fold change and FDR values were input to Ingenuity
Pathway Analysis (IPA) web-based software (QIAGEN, Hilden, Germany) with a FDR
q-value cutoff of 0.1 for inclusion in analysis. Tissues considered were CNS tissue
(not otherwise specified), cortex, and hippocampus. Enriched disease pathways and
predicted upstream regulators were filtered from a comparison analysis across all six
time points for each tissue with an activation z score absolute value > 0.
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2.2.7.4 Analysis of CCI Ipsilateral vs. Contralateral
Comparison of ipsilateral vs. contralateral expression in CCI rats was carried out using
a paired t-test. Fold change P values were corrected using Benjamini-Hochberg False
Discovery Rate (FDR).[147] A q-value of 0.05 was considered statistically significant.
2.3 RESULTS
2.3.1 Gene Expression Panel Design
The literature review identified 27 rat transporters corresponding to 24 human homo-
logues Table 2.1. To provide a limited physiological context for changes in expression,
we selected four transcription regulators known for their roles in injury and in modula-
tion of transporter expression (Nfe1l2, Hif1a, Nr1i2, Il6). To serve as validation and to
ensure adequate control for the model, we added five biomarkers (Edn1, Gfap, Vim,
Ngb, Icam1) for injury that are well characterized post injury, and four housekeepers
to normalize the expression (Ppia, Gapdh, Tbp, Hprt1).
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Table 2.1: Genes and Associated Homologues in Gene Expression Panel









































2.3.2 Expression in Naïve Rats
Baseline expression of transporters in the naïve rats was similar across the hippocam-
pus and the cortex. Overall, Slc2a1, a glucose transporter, was the most prominently
expressed in the cortex and hippocampus with no evidence of differential expression
associated with development. Multiple transporters in the organic anion transport
protein (OATP) group of transporters (Slco1a2, Slco1a5, Slco1b2) showed differen-
tial expression in the hippocampus associated with development. Among these, only
Slco1a2 was differentially expressed with development in the cortex. The peptide
transporter, Slc15a1, showed differential expression in the cortex and hippocampus
with a drop to near zero expression occurring from PND 31 to adulthood. Slc16a1, a
lactate and pyruvate transporter, was of similar expression levels to Slc2a1 in PND
17 rats, with decreases in expression from PND 17 to adulthood in hippocampus and
cortex. From PND 17 to Adulthood, 14 and 11 transporters showed differential ex-
pression associated with development in the hippocampus and cortex, respectively.
With few exceptions, the majority of these changes were associated with differential
expression from PND 17 to adult, suggesting the the PND 31 time point is an expres-
sion level intermediate within rat development. ABC transporters as a whole showed
diverse expression patterns with modeest changes with development. Among these,
transporters within the MRP group (Abcc2, Abcc4, and Abcc5) showed changes with
development in the hippocampus.
Expression patterns compared to liver and kidney were also presented to contex-
tualize the magnitude of transporter expression. Naïve expression for liver and kidney
is presented in Figures 2.2 and 2.3, respectively. Cortex baseline expression and
expression relative to liver and kidney are shown in Figures 2.4 and 2.5, respec-
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tively. Hippocampus baseline expression and expression relative to liver and kidney
are shown in Figures 2.6 and 2.7, respectively. Choroid plexus baseline expres-
sion and expression relative to liver and kidney are shown in Figures 2.8 and 2.9,
respectively. Baseline data in naïve rats showed diversity among baseline levels of ex-
pression. Slc2a1 was the highest expressed transporter in all brain tissues. Relative to
kidney and liver, all brain tissues expressed high levels of Abcc8, which had negligible

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.5: Naïve expression in rat cortex at PND-17 and PND-31 relative to liver and kidney. Statistical significance










































































































































































































































































































































































































































































































































































































Figure 2.7: Naïve expression in rat hippocampus at PND-17 and PND-31 relative to liver and kidney. Statistical









































































































































































































































































































































































































































































































































































































Figure 2.9: Naïve expression in rat choroid plexus at PND-17 and PND-31 relative to liver and kidney. Statistical
significance can be inferred from error bars (95% CI) that do not cross the zero line.
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2.3.3 Expression Changes Due to Injury
2.3.3.1 CCI vs. Sham
Eight out of nine ABC transporters showed significantly differential expression from
sham in at least one time point in hippocampus Table 2.2 and cortex Table 2.3. We
found that changes in ABC transporters were mirrored in cortex and hippocampus in all
cases, with some visually apparent variation in magnitude Figure 2.10A. ABC trans-
porters exhibited either early down-regulation followed by gradual return to baseline,
or delayed up-regulation. Interestingly, Abcb11 showed a spike in expression that was
significant in the cortex. These patterns appear to follow patterns similar to Hif1a
and Il6 Figure 2.10D. Similarly to ABC transporters, many SLC transporters showed
an early decrease in expression followed by a gradual return to baseline or an inver-
sion to over-expression Figure 2.10B. Biomarkers for TBI showed mostly predictable
changes in expression. In contrast to expectations, we found significantly decreased
expression for Ngb in both hippocampus and cortex Figure 2.10C.
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Table 2.2: Gene Expression Changes in the Hippocampus
Gene
3 Hours 12 Hours 24 Hours 72 Hours 7 Days 14 Days
Log2 FC FDR Log2 FC FDR Log2 FC FDR Log2 FC FDR Log2 FC FDR Log2 FC FDR
Abcb11 0 NA 0 NA 0 NA 0.809 0.12 0 NA 0 NA
Abcb1a -0.634 0.01 -0.812 0.002 -0.22 0.114 0.03 0.933 0.039 0.887 -0.039 0.894
Abcb1b -0.541 0.567 -1.034 0 -1.326 0 0.084 0.939 -0.194 0.415 -0.151 0.581
Abcc1 -0.114 0.582 -0.285 0.072 0.022 0.886 0.192 0.306 0.282 0.057 -0.004 1
Abcc2 -0.331 0.063 -0.49 0.056 -0.592 0.021 -0.336 0.169 -0.036 0.894 0.122 0.582
Abcc4 -0.227 0.453 -0.034 0.931 0.399 0.017 1.06 0.006 0.692 0.001 0.281 0.378
Abcc5 -0.069 0.38 -0.064 0.473 0.011 0.939 0.069 0.582 -0.07 0.451 -0.054 0.582
Abcc8 0.167 0.197 -0.154 0.197 -0.713 0.046 -0.761 0.011 -0.495 0.002 -0.343 0.222
Abcg2 -0.918 0.019 -0.924 0.093 -0.468 0.018 -0.405 0.17 0.056 0.931 -0.328 0.393
Edn1 1.256 0.006 0.239 0.577 0.838 0.005 0.124 0.708 0.15 0.554 -0.222 0.611
Gfap 0.704 0.008 2.038 0 2.351 0.001 2.836 0.001 1.916 0 1.539 0.006
Hif1a 0.407 0.003 1.024 0 0.939 0 0.536 0.042 0.171 0.006 0.284 0.392
Icam1 3.335 0 2.783 0.001 3.168 0.021 3.004 0 1.884 0 1.587 0.052
Il6 6.262 0.005 2.584 0.036 1.412 0.132 0.644 0.508 0 NA 0.869 0.509
Nfe2l2 0.836 0.001 0.896 0 0.773 0.001 1.798 0 1.148 0 0.893 0.027
Ngb -0.123 0.822 -0.84 0.004 -1.211 0.006 -0.617 0.378 -0.103 0.769 -0.759 0.016
Nr1i2 0.181 0.7 -0.076 0.939 0.327 0.508 0.036 0.943 0.853 0.007 0.039 0.939
Slc15a1 -0.278 0.378 0.224 0.762 -0.037 0.897 0.199 0.563 0.213 0.499 0.163 0.582
Slc15a2 -0.279 0.004 -1.486 0 -1.954 0 0.431 0.064 0.543 0.004 0.469 0.034
Slc16a1 -0.037 0.894 -0.539 0 -0.351 0.008 0.692 0.036 0.619 0.003 0.594 0.07
Slc22a2 0.245 0.582 -0.208 0.582 -0.054 0.939 0.772 0.489 0.362 0.637 0.189 0.858
Slc22a4 -0.034 0.976 1.044 0.018 1.338 0.001 2.32 0 1.863 0 1.787 0.003
Slc22a6 0.227 0.508 -4.589 0.002 -3.646 0.009 0.102 0.939 0.164 0.897 0.991 0.433
Slc22a8 -0.337 0.266 -1.68 0.001 -1.442 0 -0.42 0.358 0.392 0.387 -0.322 0.231
Slc28a2 0.091 0.801 -0.536 0.088 0.664 0.128 1.502 0.013 -0.247 0.392 0.169 0.563
Slc29a1 -0.702 0.143 -0.793 0.002 -0.411 0.034 0.137 0.577 0.514 0.134 0.517 0.118
Slc2a1 0.457 0.079 0.614 0.001 0.664 0.007 0.546 0.058 0.331 0.063 0.438 0.051
Slc47a1 -0.608 0.763 -0.856 0.626 1.379 0.433 2.092 0.197 0.039 1 1.382 0.387
Slc7a1 -0.132 0.301 -0.192 0.378 -0.173 0.392 -0.189 0.563 -0.163 0.566 -0.257 0.244
Slc7a5 0.327 0.022 0.613 0.001 0.694 0 0.426 0.021 0.582 0.004 0.375 0.009
Slco1a1 0.058 0.984 0.469 0.305 0.796 0.168 -0.593 0.595 -0.367 0.784 -0.368 0.701
Slco1a2 -0.988 0.009 -1.54 0 -0.775 0.016 -0.189 0.577 0.105 0.621 0.108 0.554
Slco1a5 -1.362 0.433 -0.076 0.894 0.319 0.451 -0.155 0.118 1.715 0.231 -0.399 0.399
Slco1b2 0 NA 0 NA 0.121 0.508 0.021 0.508 0 NA 0 NA
Slco2b1 -0.61 0.022 -0.884 0 -0.594 0.002 0.688 0.001 0.968 0.001 0.741 0.024
Vim 0.485 0.017 1.881 0 3.909 0 5.091 0 3.286 0 2.609 0.005
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Table 2.3: Gene Expression Changes in the Cortex
Gene
3 Hours 12 Hours 24 Hours 72 Hours 7 Days 14 Days
Log2 FC FDR Log2 FC FDR Log2 FC FDR Log2 FC FDR Log2 FC FDR Log2 FC FDR
Abcb11 0.000 NA 0.170 0.479 1.149 0.068 1.837 0.019 1.357 0.043 0.769 0.197
Abcb1a -0.187 0.583 -0.324 0.114 -0.145 0.673 0.243 0.114 0.415 0.032 0.275 0.293
Abcb1b 0.820 0.021 0.834 0.020 0.507 0.008 2.077 0.000 1.551 0.061 0.955 0.252
Abcc1 -0.180 0.333 0.090 0.405 0.321 0.003 0.421 0.013 0.269 0.070 0.189 0.410
Abcc2 -0.384 0.004 -0.505 0.063 -0.561 0.038 0.050 0.686 0.051 0.643 -0.224 0.292
Abcc4 0.186 0.401 0.156 0.377 0.260 0.207 0.775 0.004 0.597 0.004 0.474 0.270
Abcc5 -0.098 0.662 0.112 0.592 0.214 0.235 0.298 0.061 0.164 0.169 -0.009 1.000
Abcc8 0.267 0.039 0.025 0.937 -0.333 0.007 -0.231 0.019 -0.170 0.329 -0.284 0.372
Abcg2 -0.507 0.329 -0.619 0.158 -0.320 0.383 -0.267 0.214 0.074 0.852 -0.007 1.000
Edn1 1.166 0.003 1.232 0.002 0.823 0.097 0.300 0.401 0.611 0.212 -0.064 0.643
Gfap 0.411 0.092 1.768 0.000 2.156 0.020 2.699 0.002 2.495 0.004 1.834 0.051
Hif1a 0.247 0.042 0.753 0.002 1.029 0.000 0.277 0.013 0.234 0.111 0.276 0.237
Icam1 1.951 0.019 2.123 0.000 1.784 0.005 1.430 0.001 1.111 0.026 0.869 0.212
Il6 4.377 0.040 4.996 0.000 2.077 0.043 1.065 0.120 1.230 0.066 0.872 0.388
Nfe2l2 0.677 0.004 0.988 0.003 0.456 0.029 1.179 0.002 1.019 0.002 0.791 0.019
Ngb -0.139 0.468 -0.841 0.005 -1.588 0.002 0.143 0.605 0.096 0.871 -0.379 0.247
Nr1i2 0.000 NA 0.105 0.479 0.000 NA 0.268 0.592 0.085 0.852 0.306 0.479
Slc15a1 0.241 0.765 0.058 0.954 -0.172 0.925 -1.023 0.173 -1.224 0.277 0.086 0.954
Slc15a2 -0.190 0.342 -0.932 0.000 -1.155 0.002 0.677 0.004 0.809 0.011 0.497 0.024
Slc16a1 -0.042 0.806 -0.448 0.003 -0.296 0.026 0.524 0.036 0.485 0.003 0.586 0.048
Slc22a2 -0.145 0.775 -0.524 0.198 0.027 0.966 0.248 0.490 0.456 0.212 0.021 1.000
Slc22a4 0.711 0.372 1.200 0.016 1.416 0.007 2.316 0.003 1.513 0.004 1.687 0.104
Slc22a6 -0.525 0.442 -2.825 0.015 -1.602 0.008 -0.060 0.933 1.452 0.092 0.505 0.583
Slc22a8 -0.208 0.563 -1.157 0.002 -1.493 0.000 -0.429 0.053 0.205 0.563 -0.141 0.726
Slc28a2 -0.543 0.029 -0.634 0.019 -0.066 0.927 0.508 0.114 -0.080 0.673 -0.290 0.479
Slc29a1 -0.261 0.120 -0.678 0.001 0.248 0.198 0.591 0.000 0.378 0.109 0.252 0.481
Slc2a1 0.394 0.087 0.789 0.002 0.705 0.030 0.085 0.643 0.301 0.137 0.393 0.070
Slc47a1 -2.303 0.036 -0.691 0.463 -1.280 0.210 -0.571 0.204 0.921 0.270 0.435 0.662
Slc7a1 0.076 0.705 -0.053 0.716 -0.157 0.270 -0.064 0.758 -0.007 1.000 0.061 0.726
Slc7a5 0.229 0.167 0.672 0.002 0.599 0.000 0.210 0.069 0.398 0.002 0.459 0.013
Slco1a1 0.000 NA 0.000 NA 0.000 NA 0.000 NA 0.000 NA 0.000 NA
Slco1a2 -0.479 0.277 -0.889 0.004 -0.647 0.197 -0.127 0.509 0.533 0.159 0.308 0.296
Slco1a5 -0.696 0.706 -1.346 0.293 0.105 0.627 0.699 0.383 -0.516 0.827 -0.055 1.000
Slco1b2 0.327 0.784 -0.517 0.563 0.318 0.827 0.254 0.792 -1.715 0.013 -0.155 0.927
Slco2b1 -0.268 0.377 -0.637 0.002 -0.490 0.003 0.716 0.004 1.203 0.001 0.712 0.132
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Figure 2.13: Time-course expression of hippocampus and cortex Slc Transporters.
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Pathway analysis showed similar mix of enriched pathways in the cortex and hip-
pocampus with a non-zero z score. Patterns showed activations of pathways known
to decrease damage to the brain, which were more sustained in the cortex Figure
2.14. These were primarily driven by up-regulation of Il-6, Nfe2l2, and Hif1a. The
overall pathway for molecular transport in the cortex showed decreased expression
early following injury with a switch to activation later Figure 2.14A. The hippocampal
molecular transporter pathway showed immediate activation, followed by intermedi-
ate decrease, and later activation Figure 2.14B. A cursory analysis of likely upstream
regulators identified the transforming growth factor-beta 1 (max z-score: 0.902) and
beta-estradiol (max z score: 0.686) as likely upstream regulators in the cortex and
hippocampus.
63











Figure 2.14: Pathway analysis identified several enriched pathways in the ipsilateral hippocampus.
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2.3.3.2 Ipsilateral vs. Contralateral
When comparing expression in the ipsilateral cortex vs. contralateral cortex, we found
significant changes in 14 genes. Conversely, in the hippocampus we only found signif-
icant deviation in two genes. Most of these associations overlapped with the findings
in CCI vs. sham, with the exception of Abcb11 in the hippocampus, where we found
significantly increased expression over a baseline and CCI level of zero. Overall, these
findings suggest that the contralateral side behaves similarly to uninjured brain, sup-
porting the role of the CCI model as a focal injury model with minimal diffuse injury.
Findings from this analysis are summarized in Figure 2.15.
2.4 DISCUSSION
We investigated baseline transporter expression in pediatric (PND 17, PND 31) and
adult rats, and differential expression of transporters in PND 17 rats injured with the
CCI model for severe TBI across six time points. Baseline expression of transporters
was similar in the cortex and hippocampus, with several gene expression changes
associated with development from PND 17 to adulthood. With few exceptions, the
majority of ABC and SLC transporters showed early decreases in expression associated
with CCI with a gradual return to baseline. Interestingly, we found that neuroglobin
was acutely down-regulated following CCI in both cortex and hippocampus. Pathway
analysis identified similar patterns of enriched pathways and upstream regulators in
hippocampus and cortex, with probable upstream regulation driven by transforming













































































































































































































































































Ipsilateral Vs. Contralateral Hippocampus
Figure 2.15: Ipsilateral vs. Contralateral Expression at 24 hours in hippocampus
(top) and cortex (bottom).
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2.4.1 Baseline expression shows diversity with development from PND 17
to adulthood
Transporter expression in PND 17 rats was similar in relative magnitude across genes,
but showed significant intra-gene variation through adulthood. This is similar to find-
ings in the gut found by Mooij and colleagues, which show changes associated with
development alone.[148] This suggests that, similarly to the approach with gut expres-
sion of drug metabolizing genes, brain disposition of xenobiotics should be considered
when extrapolating adult doses to pediatrics.[148] This is exemplified by our findings
in the Abcc (MRP), Abcb (MDR), and Slco (OATP) transporter families, which showed
significant diversity within the hippocampus and cortex.
We found that Slc15a1 (human homologue: SLC15A1) is expressed in the brain at
PND 17 and 31, but did not detect expression in adults. This peptide uptake trans-
porter has previously been only associated with intestinal brush border expression,
but our findings suggest that it may be expressed in the brain and/or blood-brain
barrier in young rats.[149] We found that a member of the same (PEPT) family of
transporters, Slc15a2, was expressed at similar levels in all ages of rats. This is pri-
marily expressed within the brain on astrocytes and on endothelial cells on the choroid
plexus.[150] Slc15a2 transports small polypeptides and peptide-like drugs (e.g. beta-
lactam antibiotics). It’s expression in the brain is on the blood-CSF barrier and within
the brain parenchyma, and it is expressed on astrocytes in neonates only.[151] Our
finding that Slc15a1, which has similar substrates but different affinity and capacity, is
expressed in the hippocampus and cortex in pediatrics suggests that pediatric dispo-
sition of these substrates in the brain is more variable than previously thought.[149]
Additional study will be necessary to replicate and identify the localization of Slc15a1
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expression in the pediatric brain.
Collectively, these answer fundamental questions about diversity among different
brain tissues and how that changes with development. It also shows the magnitude
of expression in the brain with respect to organs (liver and kidney) with generally high
levels of transporter expression.
2.4.2 Transporter expression follows a similar pattern in hippocampus and
cortex following CCI
Overall, we found that transporter expression shows patterns of early down-regulation
followed by delayed increase in transporter expression. This is corroborated by the
pathway analysis, which showed a similar pattern of decreased and increased expres-
sion. We found that Abcb11, which is normally not present above minimum levels
in the brain, was increased with similar timing as a spike in Nfe2l2 at 72 hours post
injury.[134] While this spike was transient in the hippocampus and may not be suffi-
cient to lead to protein expression, it was sustained in the cortex following injury.
These changes in expression mirror changes in expression of transcription factors
that can impact the expression of metabolic proteins (e.g. enzymes, transporters).
Particularly, early inhibitions in expression of transporters mirror changes found in Il-6,
which is associated with decreased expression of transporters and cytochrome P-450
enzymes.[152, 128] This acute decrease in expression is likely aimed at protection of
tissue from the toxic byproducts associated with injury and tissue repair.[153] Delayed
increases in expression follow patterns, most pronounced in Hif1a.
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2.4.3 Neuroglobin expression post CCI was divergent from expectation
Our study showed that neuroglobin expression decreased in the hippocampus and
cortex following TBI. Neuroglobin is a neuro-protective hemoprotein that binds O2,
NO, and CO in the brain.[154] It can mitigate oxidative stress and hypoxia, and over-
expression is neuroprotective.[154, 155] Previous work by Di Pietro and colleagues
studied neuroglobin expression following experimental diffuse (mild and severe) TBI
in adult rats. They found increased expression of neuroglobin immediately following
injury in both the severe and mild TBI models.[154] This suggests divergence with the
brain’s response to our focal injury model (CCI) versus the response following a diffuse
injury model. This contrasts with the other biomarkers evaluated on this panel, which
followed expected patterns of expression changes.
2.4.4 Similar pathway enrichment found in cortex and hippocampus
Pathway analysis identified similar patterns of enrichment in hippocampus and cor-
tex. Upstream regulator analysis identified Tgfb1 and beta-estradiol as the most likely
expression regulators in pediatric experimental severe TBI. This is corroborated by
work by Kobori and colleagues, who found that Tgfb1 expression was increased with-
ing two hours of CCI in mice.[156] Tgfb1 is associated with decreased inducible nitric
oxide synthase (iNOS) related to activated microglia and macrophages.[157] Broader
pathway analysis carried out by Samal, et al. identified Tgfb1 as part of the lim-
ited set of ten first messengers that explains approximately 97% of downstream gene
expression changes at 24 hours post mild CCI.[158] Beta-estradiol is generally re-
garded as a neuro-protective hormone.[159, 160]. It is also associated with a rapid




While this particular project focused on the overall changes in transporter mRNA
expression, we are particularly interested in how Abcg2 is impacted by injury. Un-
derstanding how Abcg2 expression changes with animal development in addition to
changes following severe TBI will better help to understand findings in studies in the
following chapters.
We found that Abcg2 was consistently expressed at high levels in the cortex and
hippocampus at all time points tested, whereas expression in the choroid plexus
showed relatively low expression. This suggests that at baseline, the contribution
of Abcg2 to substrate efflux on the choroid plexus is lower than the brain/BBB. Warren
and colleagues studies the comparative expression of Abc/ABC transporters in rodent
and human brains. They found that Abcg2 was more highly expressed relative to
Slc2a1 in rodents than in humans.[134]
Abcg2 was remarkably consistent in the cortex and hippocampus following experi-
mental TBI. It showed significant decreased in expression at the three hour time point
following injury, but was back to baseline by the 12 hour time point. This suggests
that Abcg2 may not as sensitive as other Abc transporter to inflammation.
2.4.6 Limitations
Our pathway analysis is based on a relatively small set of genes that are centered
around transporters, thus findings are likely to be biased to those genes. Our model
of severe TBI (CCI) is a well studied focal model, but may not translate to a diffuse
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injury model. To minimize time from dissection to freezing, we rinsed tissue with
saline rather than perfusing the rats. This raises the possibility of contamination of
mRNA found in blood and can raise the risk for noise in results. For this analysis, we
did not validate changes in mRNA expression with protein expression analysis. While
the mRNA data provides insight into the biological mechanisms, it does not always
translate to changes in protein levels.
2.5 CONCLUSION
We investigated transporter mRNA expression at baseline and in experimental TBI at
acute and long term time points following injury in pediatric rats using the innovative
expression technology, Nanostring, that provides absolute transcript counts in multi-
ple brain tissues. The findings are an important step toward stronger understanding
of secondary injury following TBI in children, and draws interesting contrast to previ-
ous investigations into expression changes following TBI. Baseline expression changes
associated with development from pediatric to adulthood suggest a dynamic biochem-
ical environment that may have implications in drug development and dosing. These
baseline expression levels also differ across brain tissues suggesting that the dispo-
sition of xenobiotics and endogenous substrates is dynamic across brain regions and
barriers. Experimental TBI in pediatric rats shows patterns of acutely decreased trans-
porter expression in the cortex and hippocampus, with some divergent increases in
expression at various time points. This is associated with acute increases in the inflam-
matory cytokine, Il-6, and later increases in the transcription factor, Hif1a, suggesting
a dynamic interplay between factors that inhibit and induce expression. Changes in
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expression from the acute to chronic phase post TBI may support the use of dynamic
treatment protocols that call for variable dosing with time post injury.
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3.0 ASSOCIATION OF ABCG2 GENETICS AND CLINICAL OUTCOMES FROM
SEVERE TRAUMATIC BRAIN INJURY
[Adams SM, et al. J. Neurotrauma 2018]
Excerpts reprinted with permission from the Journal of Neurotrauma[163]
See Appendix 3 Figure C2
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3.1 INTRODUCTION
3.1.1 ABCG2 as a Mediator of Brain Recovery
ABCG2 is a transporter expressed throughout the brain and is of particular interest
because it is highly expressed at all points in human development and it may be
responsible for efflux of toxic waste products from the brain (e.g. protoporphyrin IX),
xenobiotics (e.g. rosuvastatin, glyburide), and the endogenous antioxidant, uric acid
(UA).[164, 165] With this information, three arguments can be made for the potential
role of ABCG2 in TBI: 1) ABCG2 function is critical for removal of toxic buildup of
protoporphyrin IX and dysfunction could mean increased brain toxicity; 2) ABCG2 is
a mediator of the disposition of drugs (xenobiotics) used to treat TBI, and variation
in ABCG2 function could help precision dosing; and 3) ABCG2 dysfunction promotes
higher levels of the antioxidant, UA, and better brain recovery from oxidative stress.
3.1.1.1 Protoporphyrin IX
Protoporphyrin IX (PPIX) is a required intermediary in the heme bio-synthesis pathway
and is an ABCG2 substrate.[166] Excess PPIX can cause damage through phototoxic-
ity, and liver accumulation of PPIX can cause hepatic injury through blockade of bile
ducts.[166] In the mitochondria, ferrochelatase catalyzes the chelation of iron by PPIX
to produce heme.[166] PPIX may be effluxed from the mitochondria to the cytosol by
ABCG2, and subsequently to the extracellular space by ABCG2.[166] ABCG2 function is
critical to the porphyrin homeostasis in embryonic stem cells, and ABCG2 dysfunction
can lead to excess oxidative stress due to accumulation of protoporphyrin IX.[167]
The role of PPIX in TBI is not well established, various forms have shown both
toxic and protective roles in the brain. Over-accumulation of heme byproducts may
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result from hemoglobin breakdown following brain hemorrhage/contusion, and may
contribute to secondary injury from TBI.[168] One such byproduct, PPIX chelated with
iron (hemin), may have a neuroprotective effect by inducing expression of heme
oxygenase-1 (HO-1), though this effect is only found at specific concentrations and
hemin can be toxic in amounts generated from heme breakdown associated with
hemorrhage.[169] Conversely, exogenously administered PPIX complexed with zinc
(Zn-PPIX) is an inhibitor of HO-1 and has been found to attenuate edema and BBB dis-
ruption in experimental closed head injury.[170] HO-1 is upregulated following brain
hemorrhage and TBI, and the neuroprotective effect of Zn-PPIX may stem from its
ability to attenuate this upregulation.[171]
3.1.1.2 Xenobiotics Relevant to TBI
Rosuvastatin (and possibly other statins) may have an anti-inflammatory effect post
TBI, and has been investigated in some small clinical trials with modest success.[3,
172] Rosuvastatin is a substrate for ABCG2 and its pharmacokinetics and efficacy
may be impacted by ABCG2 function. Rosuvastatin efficacy as a cholesterol lower-
ing medication has been found to be associated with the ABCG2 c.421C>A variation,
where individuals with the AA genotype have approximately 7% greater decrease in
LDL-C.[173] Zhang and colleagues showed that ABCG2 c.421C>A CA and AA geno-
types are associated with approximately 80% higher AUC (p=0.018) and 90% higher
CMAX (p=0.048).[174]
Glyburide has been investigated as potential therapeutics for TBI and has shown
strong promise in clinical trials for TBI.[3] The benefit of glyburide is thought to be
related to inhibition of the ABCC8-TRPM4 channel as a strategy to mitigate cerebral
edema.[31, 104] Pollex and colleagues investigated the impact of HEK-293 cells trans-
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fected with the ABCG2 c.421C>A variant on intracellular glyburide accumulation (an
indirect measure of ABCG2 affinity). They found that the "A" allele at c.421C>A was
associated with significantly higher accumulation, suggesting decreased affinity for
glyburide.[175] While this has not been evaluated clinically, it is possible that ABCG2
c.421C>A may have utility as a PGx predictor of glyburide pharmacokinetics. Given
that in TBI the dose of glyburide is generally lower than when used for type 2 dia-
betes, and that ABCG2 may limit its entry into the brain - it is possible the patients
with variant ABCG2 may require lower doses of glyburide to achieve adequate brain
concentrations.
3.1.1.3 Uric Acid
Uric acid is the highest abundance antioxidant present in the blood and is a significant
part of the antioxidant reserve in the brain, in addition to ascorbic acid, glutathione,
and several other compounds.[108] TBI is associated with massive generation of re-
active oxygen species (ROS), and strategies to increase the oxidative reserve post-TBI
have been popular in TBI drug development.[31, 108] ABCG2 c.421C>A is strongly
associated with risk for hyperuricemia and gout, along with several other less com-
mon variants in the ABCG2 gene.[176] This association is due to decreased ABCG2
protein expression conferring decreased renal and extra-renal (e.g. gut) clearance of
UA.[177, 178] Given the high level of expression of ABCG2 on the blood-brain barrier,
it is possible that individuals who carry an "A" allele at ABCG2 c.421C>A have higher
brain concentrations of UA at baseline, thus a more robust antioxidant reserve. Con-
versely, the "A" allele at ABCG2 c.34G>A may confer lower brain concentrations of UA
and a weaker antioxidant reserve.
76
3.1.2 Objective and Hypothesis
We were interested in studying the role of ABCG2 increased (c.34G>A) and decreased
(c.421C>A) function with regards to clinical TBI outcomes following the UA hypoth-
esis. Our objective was to determine the potential association of ABCG2 c.421C>A
and c.34G>A with outcomes following severe TBI in multiple cohorts. We hypothe-
sized that genetic variation causing decreased ABCG2 function/expression would be
associated with improved clinical outcomes (i.e. improved GOS score) following TBI.
3.2 METHODS
3.2.1 Population
This was a retrospective cohort study based on data collected from the University
of Pittsburgh Brain Trauma Research Center (BTRC) . The BTRC contains injury data,
outcomes data, and biologic samples from patients suffering from TBI who consent
to research. Subjects were identified from the BTRC following approval by local Insti-
tutional Review Board. Informed consent was obtained from the subjects’ surrogates
prior to data collection. Criteria for inclusion were: age 16 and older, Glasgow Coma
Scale (GCS) score of 8 or less in the absence of medications known to affect GCS, and
external ventricular drain (EVD) placement. To diminish the risk for population strat-
ification skewing results, only Caucasian subjects were included in the final analysis.
Patients with penetrating trauma and those with previous neurologic impairment were
excluded. Two independent cohorts were identified to provide a cohort for discovery
and replication. Cohorts were built by date of injury (separated by approximately four
years) from the same clinical site.
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3.2.1.1 Outcome Measurement
Glasgow Outcome Scale (GOS) scores were collected by qualified neuro-psychologists
3, 6, 12, and 24 months post injury. The GOS ranges from 1 to 5, where a score
of 1 corresponds to deceased, 2 corresponds to a patient in a persistent vegetative
state, 3 corresponds to a patient with severe disability, 4 corresponds to a patient with
minor disability, and 5 corresponds to little or no disability. To control for injury char-
acteristics based on pathoanatomical data, computed tomography imaging data was
reviewed for hemorrhage types associated with the injury. Patients were coded based
on the presence or absence of one or more of the following: epidural hematoma (EDH),
subdural hematoma (SDH), subarachnoid hemorrhage (SAH), intraparenchymal hem-
orrhage (IPH), intraventricular hemorrhage (IVH), and/or evidence of diffuse axonal
injury (DAI).
3.2.2 Genotyping
DNA was isolated from CSF samples taken from the EVD or from blood samples using a
commercially available kit (Qiaamp kit, Qiagen, Chatsworth, CA, USA). Genotyping for
ABCG2 c.421C>A and c.34G>A was performed with a TaqMan™allelic discrimination
assay for the discovery cohort (Applied Biosystems, Foster City, CA, USA), and a mix
of TaqMan™+ Illumina Human Core Exome v1.2 (Illumina, San Diego, CA, USA) for the
replication cohort. Genotype data quality was addressed by using technical replicates,
blinded double calls of raw data, assessment for significant deviation from Hardy-
Weinberg equilibrium. Allele frequencies were compared with published frequencies
for the non-Finnish European population from the Broad Institutes’s gnomAD Browser.
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3.2.3 Statistical Analysis
All statistical analyses were carried out using R v3.4.3 (R Development Core Team,
Vienna, Austria). Demographic data for the discovery and replication cohorts were
compared using the t-test, Chi-Square test, or Fisher’s exact test. All genetic associ-
ation studies were carried out using a dominant variant allele model (i.e. Phenotype
magnitude in CC < CA/AA). Subjects with missing hemorrhage-type data were coded
with a dummy variable to account for the missing data while avoiding list wise exclu-
sion.
3.2.3.1 Mixed Ordinal Regression Model
To determine the association of ABCG2 c.421C>A and c.34G>A with outcomes, GOS
score was treated as an ordinal variable and compared with mixed effect multiple
ordinal regression using the package Ordinal for R. Covariates in the model included
age, sex, GCS score, post-injury imaging derived hemorrhage types, and time-post
injury. All covariates were tested individually and for two-way interactions, and were
forced into the model due to their previously determined associations with TBI severity
and outcomes.[179, 180] Time post injury was also controlled for to delineate the
multiple measurements for each level of the random variable (subject ID). Skewed
continuous variables were transformed by taking the natural log to improve model fit.
Significance for random effects were determined with ANOVA of a mixed model and a
standard model excluding the random effect variable. Models were fit using adaptive
Gauss-Hermite approximation with variable Gaussian quadrature points to attain the




ordinal.model <- clmm(data, y ~ x1 + x2 + ... + xn + (1|ID), Hess = TRUE,
nAGQ = q, doFit = T)
Results are presented as model parameters and odds ratios where appropriate,
which correspond to the odds of being in any higher GOS level. Depending on the
presence of interacting terms, odds ratios will be calculated conditionally upon inter-
acting terms using
3.2.3.2 Testing for Proportionality of Odds
Ordinal logistic regression is an extension of logistic regression that allows for a multi-
level dependent variable (ordinal). This model assumes proportional odds, which
states that the odds of being in a higher level are the same. For example, with the
GOS score, proportional odds being met states that the odds of being GOS 1 vs. GOS
2, 3, 4, or 5 are the same as being GOS 1,2 vs. GOS 3, 4, or 5, and so on. While there
are multiple methods to test this assumption in simple models, at the time of this
analysis there are no well-established methods for assessing proportionality of odds
adherence in mixed ordinal regression models. Bell and Dexter suggested splitting or-
dinal variables in all possible cut-points and comparing each model for similarity (i.e.
the slopes will be the same in each model with differing intercepts.)[181] To apply this
method to our data, we dichotomized the GOS along four possible cut-points [1|2-5,
1-2|3-5, 1-3|4-5, 1-4|5], then controlled for age, sex, time, post-injury imaging deter-
mined hemorrhage types, and GCS with random effects of subjects with mixed-effects
binomial logistic regression using the LME4 package for R. Confidence intervals (95%)
of the coefficients were estimated using:
ƒ (, y) =  ± 1.96∗ y
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were compared for all coefficient estimates for each break point. The model was
controlled for time post injury, age, sex, time post-injury, imaging determined hemor-
rhage types, and GCS. If the main effects (genotype and any interaction terms) 95%
confidence intervals shared overlap, it was assumed that proportionality of odds was
met.
3.2.3.3 Univariate Assessment of Dichotomized Outcomes
To obtain a simple estimate of odds of having a favorable (GOS > 3) vs. unfavorable
(GOS < 4) outcome, we measured the proportion of subjects in each group split by
genotype and any relevant interactions found in the mixed effect model. This was
compared with the chi-square test at each time point post injury.
3.3 RESULTS
3.3.1 Demographics and Population Characteristics
The discovery and replication cohorts contained 270 and 166 subjects, respectively.
Table 3.1 shows the demographic information for each cohort.
81
Table 3.1: Cohort Demographics
Factor Discovery Cohort Replication Cohort p value
Age Median (IQR*) 33 (23-47) 36.5 (24-54) 0.03
Female (%) 21.1% 22.3% 0.86
GCS** Median (IQR*) 6 (4-7) 7 (5-7) 0.22
Hemorrhage Type
None 2 (0.7) 2 (1.2) 1
Epidural Hematoma 29 (10.7) 17 (10.2) 0.99
Subdural Hematoma 134 (49.6) 49 (29.5) <0.001
Subarachnoid Hemorrhage 132 (48.9) 43 (25.9) <0.001
Intraparenchymal Hemorrhage 65 (24.1) 39 (23.5) 0.98
Intraventricular Hemorrhage 54 (20.0) 7 (4.2) <0.001
Diffuse Axonal Injury 58 (21.5) 21 (12.7) 0.03
No Imaging Data 46 (17.0) 24 (14.5) 0.56
ABCG2 c.421C>A (CC) N (%) 227 (84.1) 128 (77.1)
ABCG2 c.421C>A (CA/AA) N (%) 43 (15.9) 38 (22.9) 0.09
ABCG2 c.34G>A (GG) N (%) 238 (93.0) 115 (92.7)
ABCG2 c.34G>A (GA/AA) N (%) 18 (7.0) 9 (7.3) 1
*IQR: Interquartile Range
Notably, subjects in the replication cohort were significantly older than the dis-
covery cohort. The frequency of the "A" (variant) allele in c.421C>A was higher in
the replication cohort than the discovery cohort, though this did not reach statistical
significance (p=0.09). We also found that the distribution of hemorrhage types were
significantly different among the two populations, suggesting that the granular injury
details differed within the populations.
ABCG2 c.421C>A and c.34G>A adhered to Hardy-Weinberg equilibrium in both co-
horts separately and combined (p > 0.05). For c.421C>A, calculated minor allele
frequencies (MAFs) were 7.96%, 12.35%, and 9.63% in the discovery, replication,
and combined cohorts, respectively. These did not significantly deviate from MAF
for ABCG2 c.421C>A in the non-Finnish European population based on the gnomAD
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Browser (discovery p=0.08, replication p=0.27, combined p=0.52). For c.34G>A, cal-
culated minor allele frequencies (MAFs) were 3.5%, 3.6%, and 3.6% in the discovery,
replication, and combined cohorts, respectively. These also did not significantly devi-
ate from the MAF for ABCG2 c.34G>A in the non-Finnish European population based
on the gnomAD Browser (discovery p=1, replication p=1, combined p=1).
3.3.2 Association of Genotype with Outcomes
3.3.2.1 Model Building
Preliminary analyses showed a significant association of c.421C>A with clinical out-
comes, but not with c.34G>A. Final model building proceeded with c.421C>A. The
final mixed effects ordinal regression model was built with covariates age, sex, time
post-injury, imaging determined hemorrhage types, and GCS forced in the model to
control for injury severity and patient characteristics that might impact recovery inde-
pendently.
3.3.2.2 Proportionality of Odds
The assumption of proportionality of odds was tested and found to be met in nearly
all cases. We found that for the time post injury variable and the X intercept had
some breakpoints where the 95% confidence interval lacked overlap. We proceeded
with the model given that the main effects (genotype) and all others met the pre-
specified assumption. The estimated confidence intervals are shown in Table 3.2. Of
note, there is missing overlap in the time post injury (Time) and the X intercept in
some measures, but all other parameters were found to overlap. Despite these minor
deviations, the assumption of proportional odds was accepted. The R code used to
calculate these is in appendix B.
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Table 3.2: The proportional odds assumption was tested by comparing
confidence intervals of each paramater at each posible breakpoint of GOS score.
Breakpoints for each model are specified with "|", where scores to the left are
coded as 0, and to the right as 1. Lower refers to the lower bound of the 95%
confidence interval estimate for the coefficient, and upper to the upper bound.
Parameter
1|2345 12|345 123|45 1234|5
Lower Upper Lower Upper Lower Upper Lower Upper
X Intercept 2.20 23.51 -1.88 16.45 -4.84 5.35 -6.58 1.90
rs2231142 -8.66 42.27 -4.74 38.27 -0.21 20.61 0.47 16.81
log Age -7.27 -1.84 -5.89 -1.22 -3.72 -1.17 -2.79 -0.69
Sex -2.96 1.94 -2.31 1.93 -0.37 2.08 -0.74 1.26
Time -0.18 -0.06 -0.05 0.04 0.09 0.15 0.10 0.16
None -8657.34 8694.92 -5165.36 5203.01 -1.60 8.70 -0.93 6.30
EDH -2.33 5.03 -2.35 3.79 -0.28 2.83 -0.13 2.35
SDH -3.03 1.63 -2.79 1.27 -1.54 0.67 -0.83 1.01
SAH -2.79 1.91 -2.43 1.66 -1.05 1.18 -1.15 0.71
IPH -1.81 3.41 -1.53 3.06 -0.45 2.04 -0.19 1.85
IVH -2.29 4.28 -2.19 3.49 -1.55 1.46 -1.36 1.11
DAI -2.71 3.51 -2.77 2.55 -0.66 2.13 -0.10 2.12
no data -4.05 3.01 -4.16 2.00 -1.55 1.79 -0.62 2.10
GCS 0.54 1.94 0.65 1.87 0.43 1.12 0.23 0.81
rs2231142*log(Age) -11.57 2.12 -10.51 1.14 -5.73 0.21 -4.73 0.09
3.3.2.3 Model Results
The final model for the discovery cohort and replication cohorts are summarized in
Table 3.3. We found a significant association with the "A" allele at c.421C>A in both
cohorts [p = 0.01 (discovery) and p = 0.02 (replication)]. Additionally, we found a
significant interaction between the presence of the "A" allele at c.421C>A and age [p
= 0.03 (discovery) and p = 0.01 (replication)].
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Table 3.3: Mixed Effect Ordinal Regression Models for Discovery and Replication
Cohorts
Factor
Discovery Cohort Replication Cohort
Coefficient (95%CI) p Coefficient (95%CI) p
ABCG2 c.421C>A 22.03 (4.53; 39.53) 0.01 25.94 (4.47; 47.42) 0.02
ln(Age) -6.69 (-9.01; -4.37) <0.001 -4.37 (-7.21; -1.53) 0.003
ABCG2 c.421C>A * ln(Age) -5.58 (-10.56; -0.60) 0.03 -8.03 (-14.18; -1.88) 0.01
GCS** Score 2.18 (1.55; 2.82) <0.001 1.47 (0.68; 2.27) <0.001
Hemorrhage Type
None 10.14 (0.95; 19.34) 0.03 2.19 (-7.05; 11.43) 0.64
Epidural Hematoma -0.37 (-2.99; 2.24) 0.78 5.40 (1.54; 9.26) 0.01
Subdural Hematoma -0.56 (-2.46; 1.35) 0.57 -1.99 (-4.78; 0.79) 0.16
Subarachnoid Hemorrhage -1.59 (-3.45; 0.28) 0.1 0.85 (-1.76; 3.47) 0.52
Intraparenchymal Hemorrhage 1.90 (-0.18; 3.98) 0.07 1.25 (-1.72; 4.22) 0.41
Intraventricular Hemorrhage 0.52 (-1.69; 2.72) 0.65 0.19 (-5.11; 5.50) 0.94
Diffuse Axonal Injury 1.48 (-0.79; 3.75) 0.2 1.04 (-2.29; 4.37) 0.54
No Imaging Data -2.55 (-5.57; 0.48) 0.1 2.32 (-1.42; 6.05) 0.22
Sex (M v. F) 1.01 (-0.99; 3.01) 0.32 -0.52 (-3.07; 2.02) 0.68
Months Post Injury 0.12 (0.09; 0.14) <0.001 0.09 (0.05; 0.13) <0.001
Subject (Random Effect) N/A <0.001 N/A <0.001
Finally, both cohorts were combined into a final group, and assessed with the same
model covariates. The coefficient for the conditional (genotype) effects were positive
(23.56, p < 0.001), and the coefficient of the interaction was negative (-6.69, p <
0.001), suggesting that the effect of genotype is mitigated by increasing age. The
final full model is summarized in Table 3.4. The odds of a favorable outcome were
much higher in younger subjects with at least one variant allele at ABCG2 c.421C>A,
and this effect is adjusted with age.
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Table 3.4: Mixed Effect Ordinal Regression for Combined Cohort
Factor Coefficient SE(95%CI) p
ABCG2 c.421C>A 23.56 6.68 (10.46; 36.66) <0.001
ln(Age) -5.93 0.92 (-7.73; -4.12) <0.001
ABCG2 c.421C>A * Age -6.69 1.89 (-10.39; 2.99) <0.001
GCS** Score 1.89 0.25 (1.40; 2.38) <0.001
Hemorrhage Type
None 5.54 3.35 (-1.03; 12.12) 0.1
Epidural Hematoma 2.12 1.09 (-0.01; 4.25) 0.05
Subdural Hematoma -0.9 0.76 (-2.39; 0.59) 0.24
Subarachnoid Hemorrhage -0.45 0.75 (-1.92; 1.02) 0.55
Intraparenchymal Hemorrhage 1.45 0.85 (-0.22; 3.12) 0.09
Intraventricular Hemorrhage 0.47 1.02 (-1.52; 2.46) 0.64
Diffuse Axonal Injury 1.16 0.97 (-0.74; 3.05) 0.23
No Imaging Data -0.31 1.15 (-2.56; 1.95) 0.79
Sex (M v. F) 0.29 0.81 (-1.29; 1.87) 0.72
Months Post Injury 0.11 0.01 (0.09; 0.13) <0.001
Subject (Random Effect) N/A N/A <0.001
The age at which the effect of age completely mitigated the genotype effect was
calculated with the following:
ge = exp(βgenotype/−βgenotype∗ge)
where β refers to coefficients from the combined cohort model defined by the sub-
script. Based on the combined model, this suggests that the age of inflextion is ap-
proximately 34 years, after which having at least one variant allele at ABCG2 c.421C>A
is predictive of a unfavorable outcome compared to those with non-variant alleles.
Note that this does not necessarily mean that the association is actually flipped, but




Age <=34 Years Age >34 Years







































Figure 3.1: When split at the age of inflection (34 years), dichotomized GOS
scores show that individuals under 34 had significant benefit from the "A" allele
at ABCG2 c.421C>A, while subjects over 34 did not have benefit or harm.
Reprinted with permission from the Journal of Neurotrauma - See Appendix 3 Figure C2
3.3.3 Age Based Assessment of Dichotomized GOS Score
Figure 3.1 shows the proportion of subjects with favorable (GOS ≥ 4) outcomes bro-
ken up by age >34 and genotype. To determine the odds ratio associated with geno-
type conditional upon subject age, odds ratios for heterozygote and homozygote vs.


















Figure 3.2: Model based odds ratios show a rapid change in benefit from the
"A" allele at ABCG2 c.421C>A with age. This allows visualization of the model
interaction.
Reprinted with permission from the Journal of Neurotrauma - See Appendix 3 Figure C2
3.4 DISCUSSION
In this study we sought to determine the association of ABCG2 c.421C>A and c.34G>A
with outcomes following severe TBI by utilizing a robust discovery-replication method.
This allowed for replication in an independent cohort and strengthens the findings.
We found similar population characteristics in the discovery and replication cohorts,
with notable differences among age and distribution of imaging derived injury severity
(i.e. hemorrhage, presence of DAI). This reflects the expected heterogeneity of the TBI
population, and the inclusion of these as covariates should provide adequate correc-
tion for associated differences. Different distributions among covariates in replicate
populations also provides an opportunity to explore the association in a more clin-
icaly representative population. Preliminary analyses through model building found
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that c.34G>A was not associated with clinical outcomes, possibly due to insufficient
power based on a lower MAF. We found that subjects with at least one "A" allele at
c.421C>A had improved odds of having a higher GOS score, and that the beneficial
effect was mitigated by increasing age to a point of inflection at approximately 34
years old. Based on the observed data versus the model, it appears more likely that
the genotype effect is present in younger individuals, and is not an important factor
in the older population, rather than a reversal of association in subjects over 34 years
old.
3.4.1 ABCG2 c.421C>A Phenotype
The molecular phenotype of ABCG2 c.421C>A is decreased ABCG2 protein expression
due to improper folding, ubiquitination, and proteasome mediated degradation.[182]
The consequence of carrying a variant allele at ABCG2 c.421C>A is decreased expres-
sion to half that of wild type ABCG2.[182] Variant alleles are associated with higher
risk for gout due to decreased renal and biliary efflux of the ABCG2 substrate, UA,
raising the risk for hyperuricemia.[178, 177]
3.4.2 ABCG2 c.421C>A Association with Other Neuro-Pathologies
Matsuo and colleagues investigated the role of ABCG2 c.421C>A in the onset of
Parkinson’s disease under the hypothesis that increased UA in the brain would pro-
vide neuro-protection. They found that patients with at least one "A" allele devel-
oped Parkinson’s disease 1.6 years later than those without a variant allele (p =
0.025).[138] This finding suggests that decreased expression and/or function of ABCG2




A potential explanation for our findings might be that people who have at least one
variant allele at ABCG2 c.421C>A have decreased efflux of UA from the brain, and
thus higher brain concentrations of UA. Increased concentrations may promote brain
recovery after TBI. Uric acid elevation therapy has been proposed as a potential treat-
ment option for multiple neurologic pathologies due to its neuro-protective effects.
Clinical trials have already investigated the use of exogenous UA as a treatment for
ischemic stroke and have provided evidence that UA therapy might prevent early is-
chemic worsening compared to placebo (p=0.01).[183]
This is supported by UA’s endogenous antioxidant activity in the brain and its role
in mitigating synaptic glutamate levels via up-regulation of the glial glutamate trans-
porters: SLC1A3 (EAAT-1) and SLC1A2 (EAAT-2). Du and colleagues also found that
inhibition of these transporters in an in vitro model for spinal cord injury promoted
apoptosis.[184] Thus, combining the antioxidant roles of UA with its anti-glutamate
effects strongly promotes the ability of UA, and thus ABCG2 in protecting the brain
following injury. Counter to this theory, Maetzler and colleagues evaluated ABCG2
c.421C>A along with variations in other UA transporters (SLC17A3 and SLC2A9) in
patients with Lewy Body Disorders (LBD). They did not find an association with ABCG2
c.421C>A, but rather found that the "T" allele at the SLC17A3 SNP, rs1165205, was
associated with higher CSF UA levels, and that subjects with LBD had lower UA levels
in serum and CSF than controls.[139] However, UA baseline serum levels are age-
dependent, and the population with LBD is generally older than study populations
with TBI.
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It is also plausible that the role of ABCG2 in regulation of amyloid-beta could explain
some of our findings. A study by Jullienne and colleagues found amyloid-beta accu-
mulation in their model for juvenile TBI.[185] The polymorphism ABCG2 c.421C>A is
thought to impact the regulation of amyloid-beta and may confer protection against
Alzheimer’s disease. Indeed, genetic risk factors for Alzheimer’s disease (e.g. APOE
ε4) are also risk factors for poor clinical outcomes from TBI, potentially related to
similar amyloid-β plaque pathology.
3.4.4 Age and TBI Outcomes
Hukkelhoven and colleagues recently showed that advancing age independently pre-
dicts unfavorable outcome. They found an age threshold of 39 years old provided the
best prediction for unfavorable outcomes and mortality.[7] Our findings provide sup-
portive data that the recovery trajectory following TBI changes in the fourth decade of
life. Future study will seek to explain the mitigation of genotype effect that happens in
patients over the age of 34. As this explanation is speculative, it does provide insight
into the potential changes in UA generation and metabolism with age. This might
relate to changes in CNS plasticity and response to injury that occur at this age.
It is also possible that this is related to a change in microglia polarization (i.e. M1
v. M2 phenotype), though this area remains controversial.[186] The response to brain
levels of UA may be age-related, wherein younger individuals might exhibit increased
sensitivity to its role in the CNS antioxidant reserve. Finally, age-related differences in
expression of compensatory mechanisms (i.e. other transport systems that compen-
sate for ABCG2) might limit the benefit of having variant alleles. Full understanding
this finding requires further mechanistic study into the biochemical disposition of pa-
tients suffering from TBI in the context of genotype at ABCG2 c.421C>A.
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3.4.5 Limitations
A limitation of our study is the single center study design. However, both groups were
independently sampled at different time points, allowing for a classical experimental
replication. Variation in fixed effects while showing the same association with simi-
lar magnitude across two heterogeneous cohorts is a strength of the findings, though
it might challenge generalizability. Similarly, the interaction between genotype and
age is interesting, but requires further study as it could result from population strat-
ification. Finally, although replication of results in a separate cohort provides strong
support of the finding, it is not possible to establish causation from a retrospective
evaluation. Further investigation into the molecular mechanism associated with the
genetic association might better explain the results of this preliminary study.
3.5 CONCLUSION
An association of ABCG2 c.421C>A with outcomes following severe TBI was identified
in a discovery and replication cohort. Mixed effects multiple ordinal regression with
GOS scores as the dependent variable showed an age*genotype interaction, suggest-
ing that having at least one ABCG2 variant allele was predictive of improved GOS
score in subjects younger than 34, and of similar or lower GOS scores in subjects over
34 years old. ABCG2 function may impact brain recovery pathways after injury in an
age-dependent manner.
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4.0 IMPACT OF ABCG2 GENOTYPE ON CNS URIC ACID CONCENTRATIONS IN
HUMANS POST TRAUMATIC BRAIN INJURY
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4.1 INTRODUCTION
To explore the potential mechanism underpinning the findings in chapter 3, we sought
to measure the disposition of the ABCG2 substrate, UA, in patients suffering from TBI.
Increasingly, UA is understood to be a critical endogenous molecule. It has pathogenic
qualities and is associated with metabolic disease, cardiovascular disease, and is the
causative agent for gout.[187, 188] However, in aqueous environments it is a potent
antioxidant and is critical for scavenging free peroxynitrite free radicals.[189]
4.1.1 Uric Acid: An Antioxidant with a Complex Past
As an endogenous product resulting from the breakdown of purines (Figure 4.1), Uric
acid has roles as a pathogenic molecule that promotes cardiovascular disease through
pro-oxidant effects and as a protective antioxidant in aqueous environments.[187]
The major disease states with which UA is implicated are gout, urinary calculi and
cardiovascular diseases.[187]
Most notable of diseases associated with UA is gout. Gout has been identified for
millenia and was thought to be related to humoral imbalance.[190] Centuries ago, Gar-
rod performed early lab testing for UA as a means of differentiating gout from rheuma-
toid arthritis.[191] Since that work, hyperuricemia has been confirmed as the precip-
itating factor of gout. This occurs as a result of UA rising above its level of solubility
and the subsequent precipitation of monosodium urate in synovial fluid, prompting
an inflammatory reaction that is alleviated by non-steroidal anti-inflammatory medi-
cations and colchicine.[192] Patients with cardiovascular disease tend to have higher
levels of UA and risk for gout. Current understanding suggests that elevated UA may
be a symptom of these illnesses, but not a causative agent.[188]
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Figure 4.1: The purine metabolism pathway ends with uric acid in humans due to a
mutation in urate oxidase. In most other mammals, allantoin is produced from uric
acid by urate oxidase.
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4.1.1.1 Evolutionary History of Uric Acid
Humans and other new-world hominids including chimpanzees, orangutans, and bono-
bos have much higher levels of serum UA than other mammals (and most other
animals).[193, 194] This ties to a mutation in the urate oxidase gene that occurred dur-
ing the Miocene era between 10 and 20 million years ago. Presence of non-functional
urate oxidase is believed to be the precipitating factor for allowing higher serum levels
of UA, which may have enabled larger, more metabolically active brains characteristic
of these hominids.[194] It has also been hypothesized by Watanabe and colleagues
that this could have conferred a survival advantage by allowing better salt and fluid
retention, which may help also explain the perceived connection between UA and hy-
pertension/cardiovascular disease.[195]
4.1.2 Potential of Uric Acid as a Mediator of Secondary Injury
Secondary injury is partly driven by increased reactive oxygen species (ROS) in the
brain.[109] Uric acid (UA) is a component of the plasma and brain antioxidant reserve
and is critical for peroxynitrite scavenging.[196, 189] The major renal and gut UA
transporter, ABCG2, is expressed on the BBB and the blood-CSF barrier.[178, 177] It
may be responsible for both the efflux of UA from brain to blood on the BBB and for the
movement of UA from blood to cerebrospinal fluid blood-CSF barrier.[135] The com-
mon genetic variant in ABCG2, rs2231142 (c.421C>A), is associated with improved
clinical outcomes following TBI, possibly due to increased brain concentrations of UA.
ABCG2 c.421C>A is a missense mutation that causes decreased protein expression of
ABCG2 and is a well-established risk factor for hyperuricemia, age of onset of Parkin-
son’s Disease, and clinical outcomes following TBI.[119, 138, 163] A link between this
variation and UA concentrations in the central nervous system (CNS) has not previ-
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ously been established.
4.1.2.1 Uric Acid is a Free Radical Scavenger
Peroxynitrite free radicals and iron generated free radicals are generated in the brain
following TBI.[197] Work by Keane and colleagues showed that UA’s peroxynitrite
scavenging may also support the integrity of the BBB, which may have relevance
in TBI due to the common disruption of the BBB post severe TBI. Uric acid relies on
the presence of ascorbic acid for the neutralization of peroxynitrite free radicals, and
ascorbate is not able to scavenge peroxynitrite at all.[198] Interestingly, UA’s antiox-
idant action is limited to aqueous environments, and it is not able to scavenge free
radicals within lipid membranes.[198]
4.1.3 Objective and Hypothesis
Our objective was to measure UA levels in the CNS in the context of severe TBI and
ABCG2 c.421C>A as a surrogate for transport capacity. We hypothesized that pres-
ence of the "CA" genotype at ABCG2 c.421C>A would be associated with decreased
CSF UA post TBI, and that decreased CSF UA would be associated with improved clin-
ical outcomes. Our expectation that UA would be decreased in the CSF is due to the
opposing localization of ABCG2 on the BBB and blood-CSF barrier, wherein ABCG2 ef-
fluxes from blood to CSF on the blood-CSF barrier and from brain to blood on the BBB.
To test this hypothesis, we needed to develop and validate a standardized method for
determining the concentration of UA in clinical samples.
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4.2 METHODS
4.2.1 Uric Acid Assay Development
4.2.1.1 Commercial Kit for Uric Acid Measurement
Measuring UA in biologic samples is not a novel undertaking. Uric acid has been mea-
sured in blood and urine in some sense for centuries.[191] We therefore approached
the need to measure UA as pragmatically as possible, starting by evaluating the avail-
able commercial tests as they may apply to this study. Initially, we sought to us the
widely available clinical tests which can be accessed through the hospital laboratory
or through commercial kits, but this proved problematic. Nearly all clinical assays
and commercial kits use enzymatic methods for determination of UA concentration.
Most commonly, they rely on the oxidation of UA to allantoin by recombinant urate
oxidase. In the presence of oxygen, this produces hydrogen peroxide, which converts
a precursor molecule to a colored dye that can be measured colorimetrically.
The problems we encountered with assay methodologies that relied on oxidation
of UA tied to the sample types we have. For the CSF samples, the expected concen-
tration is very low (1-50μM), which is achievable with some kits, but we were skeptical
of the reliability as there was no published literature where someone had used a kit
to quantify CSF UA. Specifically, the Amplex® Red UA acid assay kit documentation
suggests detection as low as 100nM of uric acid when used with the protocol for fluo-
rometric measure.[199] While this lower limit is adequate for our CSF concentrations,
we were unable to satisfactorily determine the expected performance when using CSF
with this kit. In addition, many samples were tinged with blood, which can potentially
interfere with the performance of the Amplex® Red reagent. The plasma samples
98
were also problematic for the commercial kits. Our bio-banked plasma samples were
anticoagulated with EDTA, a calcium ion chelator. EDTA also functions as an antiox-
idant itself and can compete with the reagents for hydrogen peroxide. This could
potentially bias the results, and would be difficult to correct for due to varying levels
of EDTA in each sample (i.e. blood volumes vary in the same size tube). Due to these
potential challenges, we sought to develop UA assays for EDTA plasma and CSF using
high performance liquid chromatography tandem ultraviolet detection (HPLC-UV).
4.2.1.2 Characteristics of Uric Acid and Standard Preparation
Uric acid is a small molecule (168.112 g/mol) with very poor solubility (60 mg/L in
water at 20°C). Its logP is -2.17, indicating that its solubility in non-polar solvents is
even poorer than in water. This is illustrative of the pathologic causes of gout and
urolithiasis - UA simply does not solvate well. This can be improved by the use of an
alkaline solvent. Previously published options include an aqueous solution of lithium
carbonate, potassium hydroxide, sodium hydroxide, and ammonium hydroxide.[200]
Xinhua found that at a 1.7:1 molar ratio of ammonium hydroxide to UA provided suf-
ficient alkalinity to solvate UA with no evidence for stability issues.[200] For plasma
and CSF we need to be able to make standards ranging from 1 to 600μM, so a stock
concentration of 600μM will be the minimum stock concentration to achieve. Given
that at the 1.7:1 ratio, UA still takes a significant amount of time to go into solution -
we opted to approximately double the ratio and make all UA stocks fresh with a molar
ratio of 2mM ammonium hydroxide:0.6mM UA. There is, however; no evidence that
this higher concentration of ammonium hydroxide causes instability of UA.
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4.2.1.3 Selection of Internal Standard
Similar to work by Soto-Otero and colleagues, we used 7-(β-hydroxyethyl) theophylline
(Etophylline), a theophylline derivative similar in structure to UA. This has been used
as an internal standard for several purine derivatives in HPLC-UV assays, including
caffeine.[201] It provides the needed molecular similarity, but with significantly dif-
ferent characteristics within a reverse-phase column that provides a much longer re-
tention time than UA due to its increased lipophilicity. Specifically, UA is much more
hydrophilic and will elute with the inorganic potassium phosphate buffer, whereas eto-
phylline will elute with the acetonitrile. The structures of UA and etophylline are shown
in Figure 4.2.
Figure 4.2: Uric acid and its assay internal standard, etophylline, are chemically
similar and have been previously used together in HPLC-UV.[201]
4.2.1.4 Assay Reagents and Parameters
The CSF and plasma UA assays followed similar parameters as reported by Soto-Otero,
with several modifications.[201] Both assays were run on a Waters 2695 separation
module. UV detection was performed using a Waters 247 dual λ absorbance detector.
The column used for both assays was a C18 5μm 3.9mm X 150mm column (part num-
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ber WAT046980, Waters Corporation, Milford, MA). Both assays used a 0.06M potas-
sium phosphate buffer with 2% methanol (pH approximately 5.1) as the primary mo-
bile phase with 100% HPLC grade acetonitrile with gradient. Stroke volume was 50μL
for both assays. Also for both assays, absorbance was measured on two channels,
292nm for UA and 272nm for etophylline. For samples, both assays started with 60μL
of plasma or CSF to be assayed (standards also 60μL), to which 240μL 100% acetoni-
trile was added to precipitate protein. Samples were vortexed for 30 seconds, then
centrifuged at 10,000G for 10 minutes. Supernatents were transferred to glass tubes
and dried under nitrogen at 60°C for approximately 15 mninutes. Samples were re-
constituted with the primary mobile phase, covered with paraffin film, vortexed for 30
seconds, then transferred to 300μL glass HPLC sample tubes. The auto-sampler was
maintained at 25°C for CSF and plasma samples.
CSF Assay
CSF standards were made in artificial CSF made with the reagents shown in table
4.1 with a standard curve containing 1μM, 5μM, 10μM, 20μM, 50μM, and 100μM.
Following preparation and loading into the auto-sampler, an injection volume of 100μL
was made into the HPLC circuit. The column was maintained at 28°C at a rate of
0.75mL/min with a gradient flow that started with 100% Potassium Phosphate Buffer
with addition of acetonitrile at a rate of 2% per minute for the first 2 minutes, then
3% per minute for an additional 7 minutes, and finally 2% per minute for the final
minute leaving a makeup of 24% acetonitrile and 76% potassium phosphate buffer.
This was followed by a return to 100% potassium phosphate buffer, which was run
for an additional 5 minutes for washout and re-conditioning the column (15 minute
runtime total). The standard curve was fit using the area ratio of UA to etophylline,
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weighted using: 1/2 in standard linear regression using R to minimize bias at the
lower end of the curve.









Plasma standards were made in phosphate buffered saline with a standard curve con-
taining 60μM, 90μM, 120μM, 240μM, 480μM, and 600μM. Following preparation and
loading into the auto-sampler, an injection volume of 50μL was made into the HPLC
circuit. The column was maintained at 35°C at a rate of 1mL/min with a gradient flow
that started with 100% Potassium Phosphate Buffer with addition of acetonitrile at a
rate of 2% per minute for the first 2 minutes, then 3% per minute for an additional
5 minutes, followed by a return to 100% potassium phosphate buffer, which was run
for an additional 3 minutes for washout and re-conditioning the column (10 minute
runtime total). The standard curve was fit using the area ratio of UA to etophylline
linear regression with no weighting applied using R.
4.2.2 Uric Acid Stability
4.2.2.1 Rationale
The samples used within this study have been stored consistently at -80°C and -20°C
since collection. While UA is thought to be stable in clinical serum samples for at least
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a year, we were worried about the integrity of the UA in the samples since several
had been stored for over ten years. There is also little or no data about the long-term
stability of UA in EDTA plasma or CSF. We therefore carried out two stability studies in
CSF and in EDTA plasma. This was done in the respective biological matrices, spiked
with UA stock solution to produce a high and a low concentrations.
4.2.2.2 Sample Preparation
Briefly, 4mL of pooled EDTA plasma and 4mL of pooled CSF was collected in separate
10mL centrifuge tubes. Pooled samples were vortexed for approximately 10 seconds,
then split (2mL each) into separate centrifuge tubes. A 1mM UA stock solution was
prepared in 2mM ammonium hydroxide. This was diluted to 150μM for the CSF. Finally,
400μL of the 150μM stock solution was added to the high CSF sample, and 400μL of
the 1mM stock solution was added to the high plasma sample. For the low CSF and
plasma samples, 150μL of 2mM ammonium hydroxide were added. Spiked stocks
were aliquoted into three replicates for both levels for each planned assessment. We
did not assess bench-top stability as that is not an expected storage condition of
these samples. The same stock solution was assayed after being created for a time 0
concentration for use as a comparator.
4.2.2.3 Free-Thaw Stability
Freeze thaw stability was assessed based on the recommendations in FDA Bioanalyt-
ical Method Validation Industry Guidance.[202] Three replicates of the high and low
concentration in plasma and CSF were stored at -20°C and thawed at room tempera-
ture on the bench-top for 1-2 hours, then allowed to re-freeze for at least 24 hours.
This was repeated three times in a two week period, then re-assayed.
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4.2.2.4 Storage Stability
Storage stability was assessed after continuous freezing at -20°C for 14 days and 2
months. Replicates at each level were pre-labeled for their destined measurement
time point. The maximum time point of two months was chosen due to practical
concerns with timely completion of this data, but additional aliquots are frozen and
available for later testing.
4.2.3 Subjects and Samples
4.2.3.1 Population
Subjects (N=41) for this study were selected from the population described in chapter
three (severe, non-penetrating TBI). The goal of this study was to identify the potential
mechanistic links of the genotype association with outcome, thus we sought to enrich
the population. While this is a non-random design, it increases statistical power (the-
oretically) by increasing the comparator sample size, thus decreasing the standard
deviation of the measure in the comparator group. Subjects were selected from the
first (discovery cohort), which did not have any individuals homozygous for the "A" al-
lele at ABCG2 c.421C>A so we focused on getting two nearly equal groups with 1) near
complete or complete outcomes data and 2) equal numbers of "CC" genotypes and
"CA" genotypes. This artificially inflates the minor allele frequency from an expected
0.12 to 0.25. As with the previous study, Glasgow Outcome Scale (GOS) scores were
collected at 3, 6, 12, and 24 months post injury and dichotomized to poor outcome
(1-3) or good outcome (4-5).
4.2.3.2 Plasma and CSF Samples
The first goal of this study was to assess the impact of genotype at ABCG2 c.421C>A
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on UA in the CNS. Thus, subjects were only included if they had available bio-banked
CSF collected from bagged drainage from extra-ventricular drains for part of their hos-
pitalization. Though not a requirement, we also collected bio-banked plasma from
patients for use as a contrast and a means to calculate surrogate transport capacity.
For plasma and CSF, variable numbers of samples were available per patient. We
measured each sample for CSF and the first available plasma sample using the val-
idated HPLC-UV assay. Plasma samples that had concentrations below the level of
quantification on the plasma assay were re-run on the CSF assay.
Due to the presence of hemorrhage in many patients suffering from severe TBI,
blood contamination is common within CSF. This raises the possibility of artificially
high levels of CSF UA due to the much higher concentration of UA in the blood. To
correct for this, we used a visual scale ranging from 0 to 2, with 0 = no blood (color-
less), 1 = blood tinge (slightly red or pink), and 2 = frank blood (very red). This was
evaluated with concentration using linear regression to determine if it was appropriate
to apply a correction to the measured concentrations. If blood contamination shows
significant association with UA concentrations, a correction factor will be applied to
the raw concentration values by subtracting the coefficient multiplied by the assigned
value from the visual blood scale.
4.2.4 Statistical Methods and Data Analysis
All analyses were completed using R v3.4.3 (R Development Core Team, Vienna, Aus-
tria).
4.2.4.1 Assay Validation
Assay validation was performed under the guidance of the FDA Bioanalytical Method
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Validation Industry Guidance.[202] Plasma and CSF assays were separately validated,
with no more than one validation run happening in a 24 hour period. Each validation
run consisted of a standard curve run in duplicate. For inter-day validations (2), low,
mid, and high quality controls were run with six replicates. For the intra-day valida-
tion (1), quality controls were ran with twelve replicates. Validation was determined
based on QC passes within the FDA recommended guidelines for inter- and intra-day
variations (20% for low, 15% for medium and high). Lower limit of quantitation (LLOQ)
and upper limit of quantitation (ULOQ) were determined from the lowest and high-
est points on the standard curve, respectively. These were performed in duplicate on
each validation day for a total of six replicates measured throughout the entire vali-
dation process. We did not assess for matrix effects, recovery efficiency, or process
efficiency, though it is acknowledged that these could have been carried out.
4.2.4.2 Direct Stability Studies
Per the FDA guidance, samples were run in triplicate for each measurement group.
Nominal concentrations for each level were taken from the day zero assay, which im-
mediately followed preparation of the high and low standards. These were compared
with measurements at the specified time points. Acceptance of the results and as-
sumption of adequate stability was determined by the presence of a bias of at most
15%.
4.2.4.3 Long Term Stability (Indirect)
To bridge the findings in the relatively short term stability study, we used the existing
samples available for the study to indirectly measure the stability trend. This was car-
ried out by fitting a regression equation to all plasma and CSF data points (separately)
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versus time. While individual differences exist between subjects, the slope should not
deviate substantially from zero. This provide an indirect measurement of extremely
long term (5+ years) of storage and freeze/thaws.
4.2.4.4 Descriptive Data
Population demographics and outcomes are compared with T test for normally dis-
tributed data and chi-square for categorical data. Data are presented as median +/-
interquartile range or as frequencies.
4.2.4.5 CSF Uric Acid Concentration and Genotype
CSF comparisons were based on the maximum measured UA concentration in a sub-
ject’s set of samples. This was done to minimize bias induced by some subjects hav-
ing extended time periods with samples vs. some with one or very few samples.
Maximum CSF UA levels were compared across genotype at ABCG2 c.421C>A and
evaluated with multiple linear regression controlling for age and sex.
4.2.4.6 CSF Uric Acid Concentrations and Outcomes
Max CSF UA was tested as a predictor of TBI clinical outcomes with mixed effects
logistic regression controlled for age, GCS, and time post TBI allowing for a random
intercept on subject. Due to the potential correlation between genotype and UA con-
centrations, genotype was not included in this model. The outcome variable was di-
chotomized to enhance model simplicity and ease of interpretation. This was accom-
plished by coding GOS 1-3 as an unfavorable outcome, and GOS 4-5 as a favorable
outcome.
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4.2.4.7 Surrogate Transport Capacity
Due to the expression pattern on the blood-CSF barrier versus the BBB, CSF UA was
assumed to be an inverse surrogate for brain UA. We calculated a rough estimate
of transport capacity using the plasma:CSF UA ratio, where higher numbers indicate
decreased transport of UA. A single plasma concentration measurement from patients
was used to calculate this measure. This measure was compared across genotype
controlled for age and sex with linear regression. It was also compared with outcomes
using mixed effect linear regression with the same covariates and random effects as
the CSF UA concentrations compared with outcomes.
4.3 RESULTS
4.3.1 Uric Acid Assay Validation
Both assays were validated and run on the same column several months apart. For
the CSF assay validation, there was one QC excluded in the 90μM inter-day runs, one
exclusion in the 45μM inter-day runs, and one exclusion in the 45μM intra-day run. For
the plasma assay validation, there was a single exclusion in the 75μM inter-day. All
other parameters passed within the FDA recommended criteria (Table 4.2). Illustra-
tive chromatograms are shown for the CSF (Figure 4.3) and the plasma (Figure 4.4).
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Table 4.2: Assay Validation Results
(a) CSF
Concentration 2μM 45μM 90μM
Inter-Day
Mean 1.97 44.9 90.83
SD 0.14 2.18 2.75
CV 7.11% 4.86% 3.03%
Bias -1.50% -0.22% 0.92%
Intra-Day
Mean 1.86 44.24 89.64
SD 0.09 2.42 1.26
CV 4.84% 5.47% 1.41%
Bias -7.00% -1.69% -0.40%
(b) Plasma
Concentration 75μM 300μM 585μM
Inter-Day
Mean 73.92 297.56 578.78
SD 1.83 5.03 13.29
CV 2.47% 1.69% 2.30%
Bias -1.44% -0.81% -1.06%
Intra-Day
Mean 73.55 299.17 572.42
SD 2.12 5.30 12.47
CV 2.89% 1.77% 2.18%











































Figure 4.3: Panel A shows a representative chromatogram for a CSF 50μM standard.
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Figure 4.4: Panel A shows a representative chromatogram for a plasma 240μM
standard. Panel B shows a representative unknown plasma sample.
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Assessing the standard curves from the validation runs showed linearity as low as 1μM
for the CSF assay, and 60μM in the plasma assay, up to the maximum concentration
on each assay. All standard curve values performed within 15% of the expected con-
centration. This suggests a LLOQ of 1μM in CSF and 60μM in plasma, and an ULOQ of
60μM in the CSF and 600μM in the plasma (Table 4.3).
Table 4.3: Assay Standard Curve Performance
(a) CSF
Concentration 1μM 5μM 10μM 20μM 50μM 100μM
Mean 0.99 5.1 10.07 20 50.71 96.5
SD 0.07 0.21 0.41 0.66 1.72 1.63
CV 7.41% 4.14% 4.04% 3.28% 3.39% 1.69%
Bias -0.57% 2.05% 0.75% 0.00% 1.41% -3.50%
(b) Plasma
Concentration 60μM 90μM 120μM 240μM 480μM 600μM
Mean 61.02 91.01 118.97 238.6 479.41 600.98
SD 1.5 1.21 1.89 4.14 5.65 5.43
CV 2.46% 1.32% 1.59% 1.73% 1.18% 0.90%
Bias 1.70% 1.12% -0.86% -0.58% -0.12% 0.16%
4.3.2 Uric Acid Stability
The baseline measurement in the CSF standard were 15.94±0.14μM for the low, and
40.11±0.88μM for the high. The baseline measurement in the plasma standard were
148.35±4.42μM for the low, and 237.42±19.06μM for the high. This shows that
the unadulterated initial pooled CSF concentration was 19.13μM based on [(15.94∗
2400)/2000 = 19.13] and the unadulterated initial pooled plasma concentration was
178.02μM based on [(148.35 ∗ 2400)/2000 = 178.02]. These initial concentrations
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also support the spiked concentration, showing an estimated concentration of 40.94μM
in the high CSF (2.1% higher) and 315.01μM in the Plasma (32.7% higher). The mea-
sured versus the expected concentration in the high plasma concentration are higher
than ideal, but not unexpected based on the challenges in creating a 1mM stock UA
solution. The transfer of fluid into the 2mL aliquot may also have been inaccurate. Re-
gardless, adherence to expected concentrations is not critical for this step - but rather
the consistency in measurements for downstream tests.
The freeze thaw study proceeded without issue. The maximum deviation from
the time0 concentration was a 5% lower reading in the plasma low concentration. A
summary of the findings from the freeze thaw study are shown in table 4.4.
Table 4.4: Freeze thaw stability comparisons between time point 0 and the two
week time point following three freeze thaws.
Level
Plasma CSF
Mean (μM) SD Bias Mean (μM) SD Bias
Low0 148.35 4.42 0.00% 15.94 0.14 0.00%
Low 140.24 2.58 -5.47% 15.45 0.17 -3.12%
High0 237.42 19.06 0.00% 40.11 0.88 0.00%
High 233.89 3.77 -1.49% 38.46 1.41 -4.10%
low0 and high0 refer to the initial concentrations assayed on day 0
The -20°C storage stability was completed up to 60 days following the initial freeze.
No measurements deviated beyond the acceptable limit of 15%. The findings are
summarized in table 4.5.
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Table 4.5: Uric Acid Stability Stored at -20°C for 14 and 60 days.
Level
Plasma CSF
Mean (μM) SD Bias Mean (μM) SD Bias
Low0 148.35 4.42 0.00% 15.94 0.14 0.00%
Low 14d 144.78 7.79 -2.41% 15.22 0.15 -4.53%
Low 60d 134.83 6.59 -9.11% 15.25 0.45 -4.33%
High0 237.42 19.06 0.00% 40.11 0.88 0.00%
High 14d 235.61 7.02 -0.76% 39.16 0.78 -2.36%
High 60d 233.88 3.74 -1.49% 40.74 0.79 1.56%
low0 and high0 refer to the initial concentrations assayed on day 0
Findings from the long term stability study are shown in Figure 4.5. Each year
was associated with a non-significant 0.97μM decrease in UA in the CSF (p=0.063),
and a 0.96μM decrease in the plasma (p=0.211). These suggest that there was not a

























































Figure 4.5: Panel A and B show all CSF and plasma levels assayed plotted against
the year they were collected, respectively. P values reflect the association between
year and concentration, suggesting that time is not associated with a significant
change in the average concentrations obtained.
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4.3.3 Population Demographics
Of the 41 subjects, all had at least one CSF sample available and 33 had a plasma
sample available. 68.3% of the subjects were male. The median ± IQR age in years of
the cohort was 25 +/- 19. Split by genotype, the cohort did not significantly differ in
age, sex, or GCS score. Demographics by genotype are summarized in Table 4.6.
Table 4.6: Cohort Demographics
Factor c.421C>A CC c.421C>A CA p value
Age Median (IQR*) 25 (20.75-41.5) 25 (21-32) 0.88
Female (%) 35.00% 28.60% 0.92
GCS** Median (IQR*) 6 (6-7) 7 (6-7) 0.89
Hemorrhage Type
None 1 (5%) 0 (0%) 0.98
Epidural Hematoma 1 (5%) 5 (24%) 0.16
Subdural Hematoma 10 (50%) 8 (38%) 0.65
Subarachnoid Hemorrhage 9 (45%) 7 (33%) 0.66
Intraparenchymal Hemorrhage 4 (20%) 6 (29%) 0.78
Intraventricular Hemorrhage 2 (10%) 6 (29%) 0.27
Diffuse Axonal Injury 2 (10%) 2 (10%) 1.00
No Imaging Data 4 (20%) 6 (29%) 0.78
4.3.4 CSF Uric Acid
Among the 41 subjects, 213 CSF samples were available. Raw data are plotted by
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Utilizing all CSF UA concentrations, we found that each level increase in the blood
scale was associated with a 4.53μM increased concentration (p=0.0003). Therefore,
a statistical correction was applied to the CSF concentrations to account for this. All
subsequent measurements using the CSF UA reflect the corrected values. The median
maximum UA ± IQR UA in the CSF was 19.37uM ± 14.93 in the CSF. Presence of the





























Figure 4.7: Uric Acid Concentrations in the CSF split by genotype at ABCG2
c.421C>A. The median ± IQR in the CC group was 22.07 ± 5.98 veresus 14.92 ±
22.51 in the CA group.
When controlling for age and sex, the association of CSF UA and genotype was
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maintained (p=0.022), suggesting that patients with the "CA" allele had 4.50μM lower
concentration in comparison to those the the "CC" genotype. Considering the age *
genotype interaction found in chapter 3, we evaluated this model with a genotype
* age interaction. This showed a significant genotype (p=0.001), and genotype*age






















Figure 4.8: Uric Acid concentrations plotted with increasing age to illustrate the
impact of the interaction between genotype an age. This is a log-linear
approximation and may not necessarily reflect predictions at extremes.
Due to the relatively small sample size and the risk of over-parameterizing the
model, we did not correct for bleed patterns in the outcomes models. This decision
was made due to repeated failure of model convergence, despite numerous attempts
to rescale variables. The final outcomes model was carried out using only scaled age,
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maximum CSF UA, time post injury, and a random effect based on subject ID allowing
for random intercepts. We found that concentration of UA in the CSF was associated
with decreased odds of having a favorable outcome (OR : 0.661, p = 0.021). This
suggests that for every 1μM increase in CSF UA is associated with 33.9% lower odds
of having a favorable outcome at any point following TBI. The results from this model
are shown in Table 4.7
Table 4.7: Mixed Effect Logistic Regression for CSF Uric Acid and Outcomes
Factor Odds Ratio p value
Max UA Concentration 0.661 0.021
Age 1.00 0.970
GCS 0.767 0.761
Time Post Injury 1.35 0.009
Subject (Random) NA 1
4.3.5 Plasma Uric Acid
Among the 41 subjects, 33 had at least one plasma sample available. The median
± IQR UA concentration was 90.69uM ± 48.64 in the entire population. Higher UA
levels in the plasma were associated with higher max CSF UA concentrations (β=0.17,
p=0.017), suggesting that an increase in 1μM UA in the plasma is associated with a
0.17μM increase in the CSF. Plasma concentrations are plotted by genotype in Figure
4.9.
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Table 4.8: Mixed Effect Logistic Regression for Plasma Uric Acid and Outcomes
Factor Odds Ratio p value
Plasma UA Concentration 0.97 0.485
Age 0.89 0.361
GCS 0.77 0.814
Time Post Injury 1.32 0.062
Subject (Random) NA 1
There was no significant difference in plasma concentration between genotypes
(p=0.7004), age (0.256), or sex (p=0.426). Plasma concentrations were also not as-
sociated with outcomes when switched with max CSF UA in the previous model. Re-
sults from this study are summarized in Table 4.8. Note that the age variable was not





























Figure 4.9: Uric Acid Concentrations in the Plasma split by genotype at ABCG2
c.421C>A. The median ± IQR in the CC group was 92.93 ± 49.06 veresus 88.34 ±
40.88 in the CA group.
4.3.6 Surrogate Transport Capacity
The median concentration ratio ± IQR was 0.23 ± 0.19. Right skew was corrected with
log transformation. When controlling for age and sex, the "CA" genotype at ABCG2
c.421C>A was associated with a decrease in concentration ratio of 0.071 (p=0.045).
This corresponds to a 35.6% decrease from the "CC" genotype. Beginning with a
similar model as used for CSF uric acid with outcomes, we found that the scaled log of
the concentration ratio was associated with higher odds of having a favorable outcome
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(p=0.034). Results from the complete model are shown in Table 4.9.
Table 4.9: Mixed Effect Logistic Regression for CSF:Plasma Uric Acid and Outcomes
Factor Odds Ratio p value




Time Post Injury 1.33 0.013
Subject (Random) NA 1
4.4 DISCUSSION
In this study, we sought to evaluate the association between UA disposition in the
CSF and plasma with genotype at ABCG2 c.421C>A in patients suffering from severe
TBI. Within that study, we developed an HPLC-UV assay for UA, which was validated in
CSF and EDTA plasma. We also assessed the short term, freeze-thaw, and long term
stability of UA in plasma and CSF, which showed that UA is likely stable enough for
research purposes for at least five years. In our study of UA in the CSF, we found
that lower CSF UA concentrations were associated with presence of an "A" allele at
ABCG2 c.421C>A. We also found that decreased concentrations were associated with
outcomes. Finally, we found that decreased ratio of UA in the CSF to plasma was
associated with presence of an "A" allele at ABCG2 c.421C>A.
4.4.1 Uric Acid Assay and Stability
While successful methodology for the measure of UA has been available for over a
century, the commercialized methods rely on relatively small concentrationrange of
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samples.[203] Our development of an assay specific for EDTA plasma mitigates the
issues associated with assays that rely on oxidation of UA for measurement. In addi-
tion, the use of UV detection with HPLC makes this assay able to measure lower levels
and has much less cost than using mass spectrometry.
Numerous studies have been conducted to evaluate the short term stability of
UA in clinical samples.[204, 205] These have generally found evidence that in most
samples, UA demonstrates stability as far as 30 days post collection. Gislefoss and
colleagues measured the stability of serum UA as far as 25 years after freezing and
noted that the measured levels may be nearly 8% lower than at baseline. They sug-
gest that much of the stability issue with UA relates to sample handling.[206] Our
findings suggest that our storage conditions are adequate for stability, but it is im-
portant to acknowledge the benefit of using fresh tissue samples when possible. Our
samples are also potentially protected by the presence of EDTA, a preservative that
might improve the stability of UA.
4.4.2 Uric Acid Association with Genotype
4.4.2.1 Uric Acid and Serum/Gout
Uric acid has been studied extensively within the context of genotype at ABCG2
c.421C>A. In the PAGE study, Zhang and colleagues found that presence of the "A"
allele at ABCG2 c.421C>A was associated with an increase of 0.24mg/dL of serum
UA.[207] Cheng, et al found that the "CA" genotype and "AA" genotypes were as-
sociated with a 0.35 and 0.56mg/dL increase in serum UA, respectively.[208] These
couple with the well studied and replicated association of ABCG2 c.421C>A with hy-
peruricemia and gout following injury.
We did not replicate the association of UA in the plasma with ABCG2 c.421C>A.
124
Previous investigations have shown that the "A" allele at ABCG2 c.421C>A is associ-
ated with an increase of 18.44μM UA in plasma (European-American population).[207]
Our population had a mean plasma UA of 90.45μM and standard deviation of 31.26μM.
A rough power calculation suggests an effect size of 0.59 (18.44/31.26) would require
at least 46 subjects to achieve 80% power. This suggests that our study was under-
powered to show the association of genotype with plasma UA concentration.
4.4.2.2 Uric Acid in the CSF
Notably, the association of ABCG2 c.421C>A in serum UA has not been shown previ-
ously in the CSF. Maetzler and colleagues investigated the levels of UA in the serum
and CSF of patients with Lewy Body Disorders and did not find an association with
genotype and CSF UA levels.[139] Notably, they also did not achieve adequate power
to show a significant association with ABCG2 c.421C>A an serum UA, either.[139]
In our study, we found a significant association with the "CA" genotype at ABCG2
c.421C>A and CSF UA, but not plasma UA. Notably different in our population is the
age of the subjects - which is around 10 years less on average than many of the gout
populations. Uric acid levels change significantly with age, and the other associations
with ABCG2 c.421C>A and UA are exclusively in older populations. This is further sup-
ported by the notion of age in our studies of ABCG2 c.421C>A, wherein we have found
that the associations with outcomes are limited to younger subjects.
4.4.3 ABCG2 Localization and Uric Acid Concentrations
4.4.3.1 ABCG2 on the BBB versus the blood-CSF barrier
These findings raise an important question, as we have consistently argued that the
"A" allele at ABCG2 c.421C>A is associated with better TBI outcomes due to higher
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levels of UA in the brain, thus better antioxidant reserve. Our finding that 1) the "A"
allele predicts lower concentrations in the CSF and that 2) lower concentrations in the
CSF are associated with better TBI outcomes seem to contradict this over-arching hy-
pothesis. However, this is most likely explained through the differences in localization
of the ABCG2 transporter on the BBB and the blood-CSF barrier. On the BBB, ABCG2
is well known to face the blood, thus effluxing substrates from the brain to the blood.
On the blood-CSF barrier, ABCG2 is likely CSF facing. This has been found in rodent
studies of transporter localization carried out by Tomioka and colleagues.[135] Op-
posing directionality suggests that ABCG2 dysfunction could predict a decrease in the
concentration in the CSF relative to plasma, and an increase in the brain relative to
plasma (i.e. inverse relationship between CSF and brain). Of note, this does not mean
that a drop in CSF UA corresponds to an increase in brain UA, but that the relationship
of UA concentrations in the brain and CSF are inverted with respect to the contribu-
tion of ABCG2. Regardless of ABCG2, higher levels in the plasma ought to correlate to
higher levels in both the brain and in the CSF.
4.4.3.2 Applying Decreased Transport Capacity with Localization
We found that decreased ABCG2 function, indirectly measured through the ratio of CSF
to Plasma UA levels, was associated with the "CA" genotype at ABCG2 c.421C>A. This
supports the change in directionality, as one would expect that decreased function of
ABCG2 would lead to less transport of UA from the blood to the CSF. This suggests,
but does not directly measure or prove, that there is decreased removal of UA from
the brain to blood in those with the "CA" genotype.
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4.4.4 Limitations
This study is intended to build a mechanistic argument for the genetic association be-
tween ABCG2 c.421C>A and outcomes following TBI. It is based on bio-banked sam-
ples collected incidentally, without purpose for this study. It is possible that the find-
ings are based on chance variations in UA concentrations that are driven by sample
age and/or storage conditions. Our selection process was focused on identifying pa-
tients who had complete data, CSF available, and at least one variant allele at ABCG2
c.421C>A. This suggests that our findings could be influenced by selection bias, which
could be improved by using a larger cohort of randomly selected subjects. We also
note that our decision to limit analysis to the maximum CSF UA and a single plasma
concentration time point was due to practicality and the expectation that 1) plasma
levels would not vary substantially, and 2) incorporation of later CSF samples would
bias the analysis to the lower baseline UA versus the relatively high levels found ini-
tially after injury. A more robust approach would be to collect CSF and plasma at
the same time for multiple time points, which was not possible in this case. Our sub-
ject sampling strategy was done to intentionally enrich the frequency of variant alleles
and to capture subjects with relatively complete data (e.g. outcomes collected at each
time point). This strategy theoretically narrows the variations and increases power,
but is non-random and inherently biased. While we do not expect that this drives the
findings, it does suggest that following up with a larger population with newer sam-
ples would be prudent. Finally, because all data is retrospective and observational, we
cannot say with certainty that UA is the mechanism by which ABCG2 influences out-
comes. In fact, each factor identified could be incidental or a product of confounding.
This is an inherent limitation of this study strategy, and countering these issues would
127
be impractical in a prospective randomized environment. Finally, we are limited to a
clinical sample due to the differences in UA disposition in animals commonly used for
TBI models. Therefore, we will hold to the argument that this methodology is the only
practical way to carry out this study.
4.5 CONCLUSION
We evaluated the disposition of UA in the CSF and plasma in patients suffering from
TBI. Subjects with the variant "A" allele at ABCG2 c.421C>A, which confers decreased
protein expression of ABCG2, were found to have lower concentrations of UA in the
CSF and a decreased ratio of CSF:plasma UA. Finally, these changes in UA disposition
in the CSF were associated with outcomes following injury. Overall, this study provides




5.1 KEY RESEARCH FINDINGS
5.1.1 Transporter Expression Decreases Acutely Following Experimental TBI
The first study described in this dissertation was a study of transporter mRNA ex-
pression following experimental TBI with the controlled cortical impact model for TBI.
Experimental TBI was carried out in 17 day-old rats compared with sham. Tissue from
adult naive rats and naive rats at 17 days and 31 days old were also collected. We
investigated the expression of transporter gene mRNA at six time points following in-
jury, including 3h, 12h, 24h, 72h, 7d, and 14d. We designed a gene expression panel
using the next-generation gene expression methodology from Nanostring.
We found similar magnitudes of expression among brain tissues (hippocampus,
cortex, choroid plexus). We also successfully replicated many known expression dif-
ferences between brain tissues and liver/kidney expression. This study also identified
some previously unknown changes - particularly among peptide transporters. Slc15a1
was expressed in the brain at PND-17 and 31, but not in adults. This differs from previ-
ously known expression patterns that suggested this transporter is limited to intestinal
expression. In addition to the Slc15a2 transporter, Slc15a1 transports small polypep-
tides and peptide-like drugs (e.g. beta-lactam antibiotics). This might indicate aber-
ration in the disposition of beta-lactam antibiotics post TBI. This study also identified
numerous other large and small changes in expression post injury that are of interest
in drug development for specific age groups and may help to better understand brain
development with different age groups.
Investigation of the expression patterns of transporters post TBI showed that most
transporters on our panel showed acute decrease in expression post injury. In com-
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parison to sham, over half of the transporters we investigated showed an immediate
drop in mRNA expression post TBI. Interestingly, in many cases that was followed with
a slow return to baseline or an inflection (i.e. increase in expression from sham). The
switch to over-expression was primarily found among the SLC transporters. Many of
these change appear to follow changes in transcription factors. IL-6 showed immedi-
ate spike in expression with very fast return to baseline in hippocampus and cortex,
which is a known regulator of expression of many transporters and other metabolism
related genes. Delayed induction of HIF-1a likely explains the slow return to baseline.
This study also identified some interesting expression patterns. The bile acid trans-
porter, Abcb11, is only associated with hepatic expression for obvious reasons. We
found that it was induced in the ipsilateral cortex and in the contralateral hippocam-
pus post TBI. It is unclear what role it may play in the brain post injury, though it
is possible that it is either 1) not translated to functional protein, or 2) an off-target
effect of the inflammatory pathways post injury and has no actual role in the brain.
Nevertheless, it is an interesting occurrence.
A final interesting finding was that in all injured tissues, neuroglobin was down-
regulated. As mentioned, this is counter to the existing data in this area that suggests
that neuroglobin is induced following TBI. It is likely that this finding is connected to the
injury model - CCI, and/or the disposition of the rats (e.g. age, time points, etc). Our
particular CCI model is fairly void of diffuse injury considering that the skull cap is not
replaced and the injury mechanism is very localized. The up-regulation of neuroglobin
found in other studies may be tied to diffuse injuries, which are likely to activate other
injury pathways.
The final analysis within this study investigated the canonical pathways activated
post TBI. Given our relatively small set of genes, highly enriched for transporters, it is
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unlikely that we would be able to find many fully defined pathways. However, we did
identify enrichment in pathways related to inhibition of brain damage and neuronal
cell death. This shows that this injury model causes significant damage as to activate
neural repair pathways.
5.1.2 ABCG2 c.421C>A is Associated with Outcomes Following Severe TBI
For this project, we sought to evaluate the role of the c.421C>A variation in the trans-
porter gene, ABCG2, in patients suffering from severe TBI. We sampled nearly 400
patients across two independent cohorts with two years of outcomes collected with
the GOS score. Outcomes were compared with genotype controlled for relevant clini-
cal and demographic parameters.
The major finding from this study was that the "CA" genotype at ABCG2 c.421C>A
is associated with improved GOS scores following injury (β=23.56, p<0.001) with a
significant age*genotype interaction (β=-6.69, p<0.001). This was replicated in two
cohorts and in a single combined cohort. The interaction between genotype and age
was an interesting finding. We found that the association of genotype with outcomes
was much stronger in individuals, with a diminishing effect as age progress beyond the
early 30s. Compared to previous studies of the role of age in TBI recover corroborates
this finding, further presenting evidence that age is an important factor in the brain’s
ability to repair itself from injury.
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5.1.3 ABCG2 c.421C>A is Associated with UA Disposition in CSF in Patients
with Severe TBI
Based on our finding that ABCG2 c.421C>A is associated with outcomes following se-
vere TBI, we sought to investigate the potential mechanistic link in this finding. We
hypothesized that the genetic association was related to the ABCG2 substrate, uric
acid. Uric acid is an antioxidant that is potentially important in neurologic patholo-
gies. Based on that, we measured uric acid in a subset of the patients in the original
association study. This study required the development and validation of an HPLC-UV
assay for plasma and CSF. For all measurements, we used the maximum measured
uric acid level in the CSF (among several samples per subject) and a single plasma
concentration.
The first and primary finding in this study was that the level of uric acid in the
CSF was associated with genotype at ABCG2 c.421C>A. This finding was maintained
when controlling for age and sex, and suggested that lower CSF concentrations are
predicted by the presence of the "CA" genotype. This finding supports the more re-
cent knowledge that ABCG2 expression on the BCSFB is reverse than that of the BBB
(i.e. moves substrates from blood to CSF versus from brain to blood). Therefore, this
suggests that decreased function of ABCG2 has a measurable impact of CNS levels of
uric acid.
We extended this analysis into the original outcomes measurement. That identified
lower CSF concentrations of uric acid as predictive of favorable outcomes following
TBI. This is likely in corollary with the original genotype association and makes it diffi-
cult to say if this is causative of the better outcomes, but it is certainly an interesting
finding.
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Finally, we evaluated a surrogate measurement of transport capacity by calculating
the ratio of CSF uric acid to plasma uric acid. Theoretically, this ratio would encompass
the net effect of passive + active diffusion in and out of the CSF from the blood and the
brain parenchyma. Comparing this ratio across genotypes can provide an estimate of
how much the flux changes as a result of ABCG2 dysfunction. While not as robust as a
transporter flux assay, it provides an in situ estimation of the impact of genotype. We
found that individuals with the "CA" genotype at ABCG2 c.421C>A had significantly
lower ratios, suggesting decreased CSF concentrations relative to the concentrations
in the plasma. Importantly, this indicates an actual change in the disposition of uric
acid among CNS barriers and further supports our uric acid hypothesis Figure 5.1.
134





ABCG2Direction of UA ux
Change with c.421C>A 
Variant Allele



















Figure 5.1: Flux of UA with respect to ABCG2 transport in the blood-CSF barrier (left) and BBB (right). At baseline,
ABCG2 contributes to the vectoral flux of UA from the blood to the CSF, and from the brain to blood. In the presence of
at least one "A" allele at c.421C>A, ABCG2 protein expression is reduced by half, which decreases movement of UA
via ABCG2. This predicts lower concentrations relative to blood in the CSF, and higher concentrations relative to blood





5.2 RELEVANCE TO CLINICAL CARE
Traumatic brain injury has no pharmacologic treatments that improve outcomes. Tremen-
dous efforts have been made to research every conceivable molecular pathway asso-
ciated with secondary injury following TBI with the hope of identifying a successful
treatment. Large research groups like Operation Brain Trauma Therapy have devel-
oped innovative approaches to better test treatment methodologies.[209] These in-
corporate different animal models for TBI along with a board of experts to spotlight
treatment candidates as a method for rapid translation into clinical trials.
5.2.1 Strategies to Increase Plasma/CSF Uric Acid
An obvious extension of this work is the design of therapeutic interventions that in-
crease uric acid in the CNS. Remarkably, this is not a novel approach as uric acid has
been a popular therapeutic target for neuro-pathologies. Methods that have been em-
ployed in practice and/or clinical trials include treatment with intravenous uric acid.
There is also limited data supporting the use of the purine inosine, which is a uric acid
precursor.
Intravenous uric acid has been of interest in the area of neurologic diseases and
injuries for several years. Most notably was the urico-ictus trial, a phase 2b-3 clinical
trial for uric acid following ischemic stroke.[210] The initial study did not find an as-
sociation of uric acid therapy with improved outcomes. However, subgroup analysis
found that uric acid treatment decreased infarct volume in women.[211] An addi-
tional tertiary analysis noted that evidence of benefit of very early treatment with tPA
and uric acid in decreasing early ischemic worsening, noting that earlier treatment is
more likely to prevent the increase in oxidative stress that occurs after many brain
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injuries.[183]
Perhaps a more practical measure of raising uric acid levels for long periods of
time is the use of the supplement, inosine. Inosine is a precursor to hypoxanthine
and oral supplementation with inosine is able to raise the levels of uric acid in the
serum, CSF, and presumably the brain.[212] It is also a naturally occurring compound
that is released during times of metabolic stress.[213] Inosine has even been used in a
rhesus monkey trial of cortical injury and was found to improve motor function after 14
days of recovery.[213] However, the benefit of inosine in cortical injury is not known to
be related to its ability to raise levels of UA. Inosine is an activator of the mammalian
Ste20-like protein kinase-3b (Mst3b), which regulates axonal growth.[214, 215] Later
work by Lorber and colleagues found that Mst3b is a key regulator of axonal regrowth,
suggesting a role in neural plasticity.[216] It is not known if UA, also a purine, has a role
in the Mst3b pathway. The protective role of inosine may be related to a combination
of Mst3b activation and antioxidant activity of the inosine metabolite, UA.
Inhibition of ABCG2 has been an interest since the discovery that ABCG2 is asso-
ciated with cancer cell resistance to chemotherapy.[116, 217] The ABCG2 inhibitor,
Ko143, is a relatively potent inhibitor for ABCG2; however, its in vivo stability has
presented challenge in its therapeutic use.[218] Additionally, work by Weidner and
colleagues has challenged the specificity of Ko143.[219] They found that, in addi-
tion to confirming issues with stability, Ko143 also inhibits the actions of ABCB1 and
ABCC1.[219] Successful use of ABCG2 inhibition in TBI would likely require that other
transporters, especially ABCB1 and ABCC1, be fully functional. Noteworthy to this
point is the association of ABCB1 and ABCC1 decreased function polymorphisms with
worse outcomes following TBI.[76] Other lead compounds that are specific ABCG2 in-
hibitors include PZ-39, fumitremorgin C, and multiple tyrosine kinase inhibitors.[220]
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Evaluation of ABCG2 inhibitors capable of producing a pharmacological equivalent of
the c.421C>A variation phenotype is warranted.
5.2.2 Age-Related Treatment
A common theme within each part of this study is the relationship of age and recovery
from TBI. In the study of gene expression, we focused on a pediatric model for TBI
because the recovery from TBI is known to change with age, and changes expression
likely differ among different age groups. This is further exemplified in the findings in
the final two aims, which showed that the connections of ABCG2 and outcomes are
heavily associated with injury. Indeed, the concentrations of uric acid in the serum
increase with age, regardless of other clinical parameters.[221] Nearly all studies of
the relationship of ABCG2 c.421C>A have focused on older populations, thus opening
the possibility that the contribution of uric acid to recovery following TBI are limited to
younger individuals.
5.3 FUTURE RESEARCH DIRECTIONS
5.3.1 Expansion of Expression Study
Animals models for TBI have been an active area for supporting TBI drug develop-
ment. Our first study of the expression of transporters post injury showed previously
unknown patterns of expression changes post injury. Extracting further value from this
study could be accomplished by comparing expression changes in human tissue post
injury. This can help to better plan drug trials for molecules that may be impacted by
the transporters.
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5.3.2 Development of Animal Model to study Uric Acid in Experimental TBI
Due to loss of activity of urate oxidase in humans contrasting the preserved activity
in most other mammals, rodents are unable to concentrate uric UA in the brain.[195,
194] This makes it challenging to validate our findings in experimental TBI without
also accounting for the changes in baseline UA. This would require the development
of an experimental TBI model with hyperuricemia. Hyperuricemia can be induced in
rodents with supplementation with potassium oxonate, and may be a viable method
for measuring this outcome and the impact of uric acid/inosine supplementation in
experimental TBI.[222] Urate oxidase knock-out may also be a reasonable way to
overcome this limitation, which has been successfully carried out by Lu and colleagues
in mice and leads to spontaneous hyperuricemia.[223] This model showed reasonable
survival of mice, with nearly 40% still alive at 62 weeks of age.[223]
5.3.3 Validation of Uric Acid CSF Findings
A significant weakness of our study of uric acid concentrations in the CSF and the
plasma is the risk for poor sample integrity. The value of bio-banked data and sam-
ples cannot be overstated, but findings in decades old samples ought to receive val-
idation from more robust methods. Our study also relied on the use of CSF collected
from drainage bags, which is frequently contaminated with blood and raises questions
about the room temperature stability of samples. Overall, our study was conducted
pragmatically, but would benefit from more robust follow-up. This could also aim to
correct the selection bias that might have influenced our results by collecting samples
from the entire cohort used in chapter three. Additionally, a study of prospectively col-
lected CSF samples from patients with TBI along with prospective outcomes collection
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would be of tremendous value in validating these findings.
5.3.4 Clinical Trial of Uric Acid Raising Therapy
Nevertheless, this study uncovered an important contribution from ABCG2 that is likely
related to the benefits of having higher concentrations of uric acid in the brain. Given
the accessibility and safety of inosine and uric acid therapy, a clinical trial in patients
with severe TBI may be appropriate. Alternatively, these may be given in the previ-
ously mentioned rat model for hyperuricemia with experimental brain injury. However,
it is likely that hyperuricemic animal models will not have improved outcomes as it is
likely that other changes are necessary for an organism to actually benefit from hav-
ing higher baseline uric acid levels. Therefore, a human study is both ethically and
scientifically reasonable.
5.4 COMMENTARY AND CONCLUSION
In chapter two we discussed the differences in baseline expression in of ABCG2 in
the brain in humans versus other mammals. Despite having a similar role in these
animals, humans tend to have much lower brain expression of ABCG2. Perhaps this is
related to a the much higher concentration of UA in human plasma and presumably,
other tissues. It suggests that human physiology regarding ABCG2 is tightly related to
maintaining high levels of uric acid without going too high. This argument is further
supported by the reality that animal models of hyperuricemia are associated with
inherent health problems. We propose that differential expression of ABCG2 in human
tissues is tied to maintenance of particular UA levels in tissues, particularly the brain.
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Genetic variations exist as a natural function of genetics. As per the tenets of evo-
lution, somatic mutations and germline variations do not necessarily exist for a reason
beyond chance, but their tendency to persist within a given population can point to
either 1) benign phenotype or 2) survival advantage. ABCG2 c.421C>A is relatively
common within the population (MAF = 0.1036) and despite its increase in the risk for
gout, does not have any pathogenic association that is known.[136] The variant is also
present in virtually every population, suggesting that, despite its functional status, is
not faced with negative selection pressure. While this alone does not suggest a sur-
vival advantage, it does raise interesting question of whether this variation supports
an enhanced neuro-protective role of UA. Deeper analysis of the potential evolution-
ary role of ABCG2 and this variation are beyond the scope of this dissertation, but do
pose interesting questions for better understanding human brain development.
Overall, we sought to determine the connection of transporters and TBI, with a
focus on the role of ABCG2 post injury. Transporters have an important role in normal
and pathogenic brain physiology, and ABCG2 is central to many of those effects. The
connection of ABCG2 to injury progression and recovery identify uric acid as a player
following TBI. It supports antioxidant reserve as a viable treatment target for TBI,
which has already been a popular target with trials existing targeting glutathione with
N-Acetylcysteine. This overall research project has extended the knowledge of the
contribution of transporters to recovery following brain injuries, and has provided new





Table A1: Ipsilateral Hippocampus Normalization Comparison
CodeCount.method Background.method SampleContent.method cv.pos.results cv.hk.results cv.end.results cv.bio2tech.ratio
geo.mean max housekeeping.geo.mean 1.7 1.3 15.3 9
geo.mean max housekeeping.sum 1.6 1.4 15.1 9.44
geo.mean max low.cv.geo.mean 1.6 1.7 15.1 9.44
geo.mean max top.geo.mean 2.9 3.6 15.6 5.38
geo.mean max top.mean 7.8 8.7 20.8 2.67
geo.mean max total.sum 7.8 8.7 20.8 2.67
geo.mean mean housekeeping.geo.mean 1.7 1.2 14.3 8.41
geo.mean mean housekeeping.sum 1.6 1.4 14.3 8.94
geo.mean mean low.cv.geo.mean 1.5 1.5 14.1 9.4
geo.mean mean top.geo.mean 2.3 3.1 13.5 5.87
geo.mean mean top.mean 7.7 8.6 18.7 2.43
geo.mean mean total.sum 7.7 8.6 18.7 2.43
geo.mean mean.2sd housekeeping.geo.mean 1.7 1.3 15.5 9.12
geo.mean mean.2sd housekeeping.sum 1.7 1.5 15.2 8.94
geo.mean mean.2sd low.cv.geo.mean 1.6 1.7 15.3 9.56
geo.mean mean.2sd top.geo.mean 2.9 3.7 15 5.17
geo.mean mean.2sd top.mean 7.8 8.7 19.7 2.53




Table A2: Ipsilateral Cortex Normalization Comparison
CodeCount.method Background.method SampleContent.method cv.pos.results cv.hk.results cv.end.results cv.bio2tech.ratio
geo.mean max housekeeping.geo.mean 3.1 0.9 15.3 4.94
geo.mean max housekeeping.sum 3.1 1 15.4 4.97
geo.mean max low.cv.geo.mean 3.2 1.2 15.1 4.72
geo.mean max top.geo.mean 3.3 2.5 14.3 4.33
geo.mean max top.mean 7.8 6.9 16.7 2.14
geo.mean max total.sum 7.8 6.9 16.7 2.14
geo.mean mean housekeeping.geo.mean 3.1 0.9 19.4 6.26
geo.mean mean housekeeping.sum 3.1 1 19.3 6.23
geo.mean mean low.cv.geo.mean 3.2 1.2 19.2 6
geo.mean mean top.geo.mean 3.3 2.5 18.6 5.64
geo.mean mean top.mean 7.7 6.8 21.2 2.75
geo.mean mean total.sum 7.7 6.8 21.2 2.75
geo.mean mean.2sd housekeeping.geo.mean 3.1 0.9 13.6 4.39
geo.mean mean.2sd housekeeping.sum 3.1 1 14 4.52
geo.mean mean.2sd low.cv.geo.mean 3.2 1.2 13.8 4.31
geo.mean mean.2sd top.geo.mean 3.3 2.5 13.3 4.03
geo.mean mean.2sd top.mean 7.8 6.9 16.4 2.1




Table A3: Raw Naïve Count Data (Part 1)
Age ID Tissue Abcb11 Abcb1a Abcb1b Abcc1 Abcc2 Abcc4 Abcc5 Abcc8 Abcg2 Slc15a1 Slc15a2 Slc16a1 Slc22a2
17 EMPXP-17 Choroid Plexus 0 9.888 3.253 8.541 6.172 8.09 8.155 6.946 8.393 0 9.291 11.63 7.39
17 EMPXP-41 Choroid Plexus 0 10.29 1.066 8.987 4.005 8.679 8.178 5.631 7.585 0 8.837 11.72 9.546
17 EMPXP-57 Choroid Plexus 0 8.166 3.765 9.983 4.823 8.324 7.557 5.998 5.277 5.294 8.324 10.52 6.94
17 EMPXP-89 Choroid Plexus 0 9.572 0 8.79 0 7.22 7.837 5.842 6.556 0 8.905 11.14 8.708
31 EMPXP-33 Choroid Plexus 0 6.405 3.516 9.354 4.173 7.73 6.771 5.747 4.928 5.285 7.308 8.925 5.51
31 EMPXP-42 Choroid Plexus 0 9.632 1.852 9.765 4.717 8.151 7.728 5.111 6.921 5.89 7.924 9.466 9.352
31 EMPXP-65 Choroid Plexus 0 9.244 0 8.481 4.223 7.305 8.264 6.293 6.886 0 8.597 10.8 10.55
31 EMPXP-81 Choroid Plexus 0 7.304 2.103 10.07 4.366 8.532 6.93 3.588 5.272 5.889 7.836 8.366 7.626
17 EMPXP-17 Cortex 0 8.744 4.73 9.327 7.678 7.415 9.835 8.796 8.071 3.599 9.045 10.86 4.321
17 EMPXP-41 Cortex 0 8.165 4.755 8.833 7.197 6.91 9.343 8.337 6.766 2.531 8.948 10.57 4.439
17 EMPXP-57 Cortex 0 8.734 5.281 9.067 7.403 7.348 9.636 8.576 6.508 2.869 8.867 11.39 4.259
17 EMPXP-89 Cortex 0 8.687 4.544 8.834 7.17 7.149 9.399 8.509 7.485 1.577 8.721 10.61 4.408
31 EMPXP-33 Cortex 0 8.753 4.31 9.033 7.709 6.912 9.756 8.572 6.727 0.7653 8.789 10.28 4.436
31 EMPXP-42 Cortex 0 9.073 3.588 9.254 7.875 6.54 9.754 8.418 7.083 0 9.244 9.87 4.966
31 EMPXP-65 Cortex 0 9.035 4.6 8.932 7.744 7.051 9.556 8.292 6.593 0 9.029 10.19 5.077
31 EMPXP-81 Cortex 0 8.864 3.754 9.148 7.984 6.914 9.752 8.708 6.549 0 8.873 10.46 5.126
A EMPXP-100 Cortex 0 9.443 3.634 8.961 8.119 6.519 9.68 8.424 7.773 0 9.351 9.865 4.215
A EMPXP-101 Cortex 0 9.431 4.469 9.356 8.065 7.23 9.884 8.57 6.781 0 9.27 10.03 4.812
A EMPXP-102 Cortex 0 9.198 3.339 9.109 7.818 6.262 9.793 8.323 7.714 0 8.994 9.933 4.725
17 EMPXP-17 Hippocampus 0 7.964 1.865 9.477 7.17 7.445 10.17 8.205 7.813 4.144 8.89 11.06 3.74
17 EMPXP-41 Hippocampus 0 8.208 8.557 9.576 6.968 7.705 10.47 8.801 7.209 5.343 9.59 10.78 3.36
17 EMPXP-57 Hippocampus 0 8.506 8.157 9.344 7.321 7.347 10.17 8.645 7.082 4.875 9.357 11.19 5.324
17 EMPXP-89 Hippocampus 0 8.561 8.174 9.213 7.299 7.203 10.43 8.557 7.841 4.425 9.463 10.71 4.087
31 EMPXP-33 Hippocampus 0 8.326 8.4 9.49 7.129 7.045 10.56 8.827 6.362 4.972 9.634 10.42 4.481
31 EMPXP-42 Hippocampus 0 8.263 8.523 9.303 7.22 6.865 10.57 8.412 6.949 4.842 9.828 9.974 5.008
31 EMPXP-65 Hippocampus 0 8.389 7.807 9.219 7.794 7.29 10.47 8.633 6.677 4.875 9.757 10.52 3.411
31 EMPXP-81 Hippocampus 0 8.42 7.583 9.055 7.654 7.054 10.57 8.425 6.576 4.749 9.762 10.6 5.232
A EMPXP-100 Hippocampus 0 9.328 8.798 9.308 7.801 6.736 9.838 8.852 8.001 0 9.856 10.17 4.713
A EMPXP-101 Hippocampus 0 9.142 8.628 9.393 7.964 6.966 9.902 8.707 6.627 0 9.856 10.13 4.977
A EMPXP-102 Hippocampus 0 9.416 8.119 9.237 8.202 6.496 10.04 8.974 8.114 2.855 9.64 10.27 4.749
A EMPXP-103 Hippocampus 0 9.417 8.295 9.352 8.022 6.98 10.09 9.059 7.157 1.511 9.525 10.32 4.332
17 EMPXP-17 Kidney 0 7.136 3.21 9.073 7.237 9.501 9.358 0 9.165 5.532 9.632 8.572 9.718
17 EMPXP-41 Kidney 8.86 6.856 0 8.979 9.154 9.31 8.875 0 8.826 5.026 9.356 9.712 9.51
17 EMPXP-57 Kidney 0 7.011 2.542 9.063 7.294 9.283 8.41 0 8.885 5.245 9.865 8.692 9.824
17 EMPXP-89 Kidney 2.987 7.144 2.316 9.046 7.496 9.224 9.262 0 9.252 5.412 10.16 8.396 9.836
31 EMPXP-33 Kidney 4.312 7.7 2.256 8.824 7.925 9.989 7.734 0 10.94 5.909 10.39 9.231 12.94
31 EMPXP-42 Kidney 3.843 7.894 2.856 8.791 7.856 10.09 7.224 0 10.78 5.641 10.67 7.918 12.89
31 EMPXP-65 Kidney 2.36 7.998 3.36 8.717 7.914 9.769 7.638 0 10.73 5.896 10.41 8.203 12.76
31 EMPXP-81 Kidney 3.58 7.605 0 8.707 7.718 9.52 7.501 0 10.79 4.802 10.27 9.753 12.52
17 EMPXP-17 Liver 11.19 7.143 0.224 6.201 11.17 4.031 9.041 0 8.918 3.224 1.809 11.1 1.809
17 EMPXP-41 Liver 11.2 6.854 0 5.739 10.61 3.656 8.985 0 9.161 4.099 0 11.1 3.013
17 EMPXP-57 Liver 10.88 7.537 1.952 6.06 10.84 4.2 8.985 0 8.859 3.122 0 11.26 0
17 EMPXP-89 Liver 10.62 6.77 0 5.786 10.43 4.064 8.851 0 8.421 2.673 0 10.51 0
31 EMPXP-33 Liver 12.48 8.737 6.369 5.745 12.64 6.619 5.067 0 9.274 4.745 0 11.59 0
31 EMPXP-42 Liver 11.83 8.944 5.685 5.482 12.69 7.841 5.482 0 8.825 4.002 0 10.5 1.754
31 EMPXP-65 Liver 11.95 8.158 5.34 5.279 12.45 6.306 5.535 0 8.618 4.461 0 10.77 0




Table A4: Raw Naïve Count Data (Part 2)
Age ID Tissue Slc22a4 Slc22a6 Slc22a8 Slc28a2 Slc29a1 Slc2a1 Slc47a1 Slc7a1 Slc7a5 Slco1a1 Slco1a2 Slco1a5 Slco1b2 Slco2b1
17 EMPXP-17 Choroid Plexus 7.157 10.02 9.588 6.568 8.028 12.17 7.547 7.797 9.744 0 9.372 2.316 0 9.058
17 EMPXP-41 Choroid Plexus 7.564 11.71 10.28 7.358 8.718 12.38 8.136 7.626 9.66 0 10.89 1.066 0 9.124
17 EMPXP-57 Choroid Plexus 6.374 8.866 11.39 5.828 8.105 10.54 6.794 6.711 8.534 0 7.899 12.57 0 7.273
17 EMPXP-89 Choroid Plexus 7.097 10.37 9.046 6.354 8.849 11.95 8.505 5.842 9.864 0 8.924 0 0 7.798
31 EMPXP-33 Choroid Plexus 5.758 7.687 10.94 6.161 7.127 10.1 8.321 4.752 8.437 0 6.845 12.28 2.763 5.969
31 EMPXP-42 Choroid Plexus 6.078 10.94 11.82 7.189 7.742 11.14 10.03 5.839 8.14 0 10.51 12.23 0 8.582
31 EMPXP-65 Choroid Plexus 8.064 11.96 11.12 8.31 8.597 11.08 9.773 4.223 8.597 0 11.1 0 0 8.738
31 EMPXP-81 Choroid Plexus 6.508 9.192 11.76 5.207 7.19 10.08 7.752 4.366 8.177 1.781 8.741 13.05 0 6.847
17 EMPXP-17 Cortex 4.73 7.175 8.957 8.441 7.108 10.92 4.118 8.753 9.558 0 7.3 3.882 2.09 8.374
17 EMPXP-41 Cortex 4.162 6.928 8.527 7.604 6.607 10.36 4.489 8.475 9.364 0 7.219 0 2.709 8.285
17 EMPXP-57 Cortex 5.159 6.852 8.971 7.927 6.947 10.43 5.394 9.234 9.355 0 7.721 0.8293 2.704 8.471
17 EMPXP-89 Cortex 4.257 6.777 8.738 8.086 6.701 10.81 4.669 8.537 9.419 0 7.03 0 2.699 7.785
31 EMPXP-33 Cortex 5.378 7.124 8.891 8.378 6.471 10.49 5.346 8.053 9 0 8.458 0 1.813 7.971
31 EMPXP-42 Cortex 4.966 7.321 8.986 8.136 7.094 10.63 5.371 7.799 9.162 0 8.665 0 0.9249 8.384
31 EMPXP-65 Cortex 5.916 6.593 8.441 7.732 6.779 10.51 3.682 8.21 8.92 0 8.72 0 2.834 8.433
31 EMPXP-81 Cortex 5.339 6.806 8.801 8.232 6.952 10.61 5.448 8.524 9.044 0 8.866 0 1.988 8.377
A EMPXP-100 Cortex 5.533 6.352 8.662 7.913 6.862 10.66 3.443 7.788 8.818 0 8.708 2.645 1.267 8.216
A EMPXP-101 Cortex 6.298 6.365 8.948 8.474 7.064 10.72 1.481 8.096 9.006 0 8.948 7.38 3.355 8.266
A EMPXP-102 Cortex 6.274 5.885 8.387 8.045 6.647 10.57 4.451 8.016 8.679 0 8.579 0 2.086 8.135
17 EMPXP-17 Hippocampus 5.446 4.31 8.697 5.765 8.628 11.07 0 8.055 9.619 0.5698 7.848 7.757 0 8.551
17 EMPXP-41 Hippocampus 5.627 6.247 8.498 7.457 5.985 10.9 1.425 8.877 9.972 0 7.953 4.051 0 8.533
17 EMPXP-57 Hippocampus 4.875 7.051 8.951 7.355 6.286 10.62 5.215 9.155 9.842 1.049 8.172 4.43 0 8.574
17 EMPXP-89 Hippocampus 4.348 5.872 8.454 7.278 5.757 11.26 0.3379 8.353 9.652 1.812 8.008 4.499 0 8.477
31 EMPXP-33 Hippocampus 6.458 5.377 7.957 7.324 5.628 10.96 4.06 8.461 9.508 0 8.977 4.406 0 8.627
31 EMPXP-42 Hippocampus 6.073 5.531 8.011 7.592 5.261 10.81 1.672 8.05 9.366 1.672 9.07 3.472 0 8.544
31 EMPXP-65 Hippocampus 7.016 6.353 8.148 7.585 6.081 10.92 5.558 8.254 9.774 0 9.089 4.103 0 8.853
31 EMPXP-81 Hippocampus 6.348 6.855 8.537 7.55 6.145 10.89 5.104 8.197 9.202 1.185 9.293 6.576 0 8.393
A EMPXP-100 Hippocampus 6.708 3.826 8.035 7.99 6.84 10.88 1.093 8.7 9.351 0 9.043 2.05 0.1759 8.788
A EMPXP-101 Hippocampus 7.179 3.176 7.898 8.256 6.994 10.78 0 8.325 9.311 0 8.934 0 1.488 8.632
A EMPXP-102 Hippocampus 7.189 5.541 8.26 8.392 7.1 10.81 5.435 8.531 9.187 0 8.766 0 2.336 8.526
A EMPXP-103 Hippocampus 7.007 4.387 7.855 8.478 7.109 10.92 1.511 8.594 9.344 0 9.016 0 2.761 8.423
17 EMPXP-17 Kidney 7.789 12.09 12.96 5.532 7.007 9.477 11.01 6.877 5.911 2.474 2.889 4.412 2.696 7.905
17 EMPXP-41 Kidney 7.359 11.83 12.76 7.166 7.117 9.211 10.69 5.826 5.944 7.04 7.178 4.731 9.984 8.986
17 EMPXP-57 Kidney 7.677 11.99 12.86 5.284 6.916 9.283 11.09 6.129 5.593 0 3.158 4.105 2.542 7.413
17 EMPXP-89 Kidney 7.826 11.66 12.77 6.215 6.951 9.824 11.28 6.403 5.823 0.368 4.131 3.789 4.455 8.563
31 EMPXP-33 Kidney 8.742 12.77 12.85 5.834 6.09 9.444 12.27 4.997 5.321 10.89 1.915 4.383 2.763 6.705
31 EMPXP-42 Kidney 8.678 12.58 12.79 5.641 5.581 9.292 12.14 4.836 5.699 10.78 3.362 4.121 2.637 6.31
31 EMPXP-65 Kidney 8.638 12.71 12.94 5.497 6.247 9.424 12.21 5.845 5.592 10.56 3.208 3.738 2.845 6.696
31 EMPXP-81 Kidney 8.359 12.45 12.53 5.494 6.376 9.259 12.04 4.802 5.089 10.34 3.72 1.102 3.049 6.266
17 EMPXP-17 Liver 3.924 0 10.46 8.595 5.509 6.853 0 0 6.414 9.091 8.999 5.031 12.56 10.65
17 EMPXP-41 Liver 4.511 0 10.24 8.828 3.202 6.989 0 0 6.411 9.217 8.929 3.894 12.23 10.58
17 EMPXP-57 Liver 3.759 0 10.09 8.102 5.344 6.652 0 0 6.581 9.38 9.658 4.537 12.4 10.52
17 EMPXP-89 Liver 4.186 0 9.372 8.943 4.299 6.354 0 0 6.808 9.187 8.79 2.973 12.06 10.19
31 EMPXP-33 Liver 6.888 0 12.72 10.17 7.832 6.289 0 0 5.967 11.01 11.9 5.247 14.1 10.91
31 EMPXP-42 Liver 6.369 0 11.98 9.058 6.983 6.076 0 0.754 6.398 10.43 11.28 4.076 13.27 10.33
31 EMPXP-65 Liver 6.423 0 12.22 9.413 8.079 6.178 0 0 5.84 10.52 11.06 4.461 13.66 10.63





EXTENDED DATA FROM ABCG2 GENETIC ASSOCIATION






for (model in model_list) {
se <- sqrt(diag(vcov(model)))
LL <- data.frame(t(fixef(model) - 1.96 * se))




LL.df <- rbind(LL.df, LL)
UL.df <- rbind(UL.df, UL)




limits <- rbind(LL.df, UL.df)
for (param in params) {
rows <- reshape(








data = c(rows[, paste(param, "upper", sep = ".")],




# Recursively test for interval overlap
apply(intervals, 1, function(v0) {
apply(intervals, 1, function(v1) {
if (v0[1] < v1[2] & v0[2] < v1[2]){
pass <- FALSE
}














prop1_2345 <- glmer(data = proptest,
GOS1_2345 ~ rs2231142_dc * log(Age) +
Sex + Time + None + EDH + SDH + SAH +
IPH + IVH + DAI + no_data + GCS + (1|IDENT),
nAGQ = 0, family = binomial, control = glmerControl(optimizer
= "bobyqa", optCtrl = list(maxfun=2e5)),
verbose = TRUE)
prop12_345 <- glmer(data = proptest,
GOS12_345 ~ rs2231142_dc * log(Age) +
Sex + Time + None + EDH + SDH + SAH +
IPH + IVH + DAI + no_data + GCS + (1|IDENT),
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nAGQ = 0, family = binomial, control = glmerControl(optimizer
= "bobyqa", optCtrl = list(maxfun=2e5)),
verbose = TRUE)
prop123_45 <- glmer(data = proptest,
GOS123_45 ~ rs2231142_dc * log(Age) +
Sex + Time + None + EDH + SDH + SAH +
IPH + IVH + DAI + no_data + GCS + (1|IDENT),
nAGQ=0, family = binomial, control = glmerControl(optimizer =
"bobyqa", optCtrl = list(maxfun=2e5)),
verbose = TRUE)
prop1234_5 <- glmer(data = proptest,
GOS1234_5 ~ rs2231142_dc * log(Age) +
Sex + Time + None + EDH + SDH + SAH +
IPH + IVH + DAI + no_data + GCS + (1|IDENT),
nAGQ = 0, family = binomial, control = glmerControl(optimizer
= "bobyqa", optCtrl = list(maxfun=2e5)),
verbose = TRUE)
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completion of the licensed use, User shall either secure a new permission for further use of
the Work(s) or immediately cease any new use of the Work(s) and shall render inaccessible
(such as by deleting or by removing or severing links or other locators) any further copies of
the Work (except for copies printed on paper in accordance with this license and still in
User's stock at the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is responsible
for identifying, and seeking separate licenses (under this Service or otherwise) for, any of
such third party materials; without a separate license, such third party materials may not be
used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for the
new work containing the republished Work are located. Failure to include the required notice
results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated
damages for each such failure equal to twice the use fee specified in the Order Confirmation,
in addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
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tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR
INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR
LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of
a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon
notice thereof may be liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any
reason (including, for example, because materials containing the Work cannot reasonably be
recalled) will be subject to all remedies available at law or in equity, but in no event to a
payment of less than three times the Rightsholder's ordinary license price for the most
closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses
incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
RightsLink Printable License https://s100.copyright.com/CustomerAdmin/PrintableLicenseFrame.jsp?...




Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions already
secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online here: http://www.copyright.com/content/cc3/en/tools/footer
/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a
separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought, at
CCC's sole discretion, in any federal or state court located in the County of New York, State
of New York, USA, or in any federal or state court whose geographical jurisdiction covers
the location of the Rightsholder set forth in the Order Confirmation. The parties expressly
submit to the personal jurisdiction and venue of each such federal or state court.If you have
any comments or questions about the Service or Copyright Clearance Center, please contact
us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions? customercare@copyright.comor  +1 - 855- 239- 3415 (tol l free in the US)  or
+1-978-646-2777.
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